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ABSTRACT 
 
Most of the biological systems in nature are sustained by molecular self-assemblies 
which are the finest examples of supramolecular architectures. Non-covalent interactions 
are key concepts which govern these molecular assemblies. Inspired by these examples 
crystal engineering emerged as an important tool in supramolecular chemistry which aids 
in the invention of new molecular structures with desired properties. Understanding of 
how the molecules interact at the molecular levels enables one to rationally design novel 
solid forms with modulated physicochemical properties. This feature of crystal 
engineering has heightened its position in materials chemistry and is currently one of the 
most well studied fields for generating novel compounds with pre-defined composition 
and supramolecular architectures. 
One such class of compounds that has immensely attracted the scientific 
community and is under continuous study for wider applications is cocrystals.  The 
applications include various interdisciplinary fields such as pharmaceutics, catalysis, 
organic conductors, explosives etc. Distinctly on the other side, cocrystals also provide a 
means to discover new supramolecular synthons which is the ultimate key to molecular 
assembly. Many robust supramolecular synthons have been discovered and hierarchies 
are also being developed which can serves as a design tool for cocrystal synthesis. The 
Cambridge Structural Database (CSD) is an important accessory in determining the 
robustness of a supramolecular synthon but, this does not preclude us from discovering 
new synthons.  
 xii 
 
The work presented here explores new persistent supramolecular synthons in 
polyphenols utilizing the basic concepts of crystal engineering and the CSD statistical 
analysis. This contribution also includes the implementation of cocrystallization for 
various categories of compounds which includes nutraceuticals, pharmaceuticals and 
ionic salts for the design and synthesis of molecular and ionic cocrystals. 
Chapter 1 highlights how supramolecular synthon approach can be used to design 
and synthesize multi-component crystals, namely, cocrystals. The role of the CSD and its 
importance in crystal engineering has also been discussed. Chapters 2 and 3 focus on new 
persistent supramolecular synthons in the context of nutraceuticals. The cocrystals 
isolated in the study are also compared with the existing cocrystals in the CSD 
supramolecularly in terms of synthon formation. These persistent supramolecular 
synthons are helpful in developing hierarchies which could be utilized and applied to 
similar and analogous compounds. The main feature of Chapter 4 is expanding the field 
of cocrystallization by studying the properties of cocrystals. Some of the properties which 
have been examined here include effects of cocrystallization on solubility and 
correlations between the solubility of cocrystal with cocrystal former (CCF) and melting 
point of the cocrystal. The extension of cocrystals to the active pharmaceutical 
ingredients (APIs) has been explored in the context of pharmaceutical cocrystals by 
selecting a BCS class IV drug, hydrochlorothiazide in Chapter 5. Chapter 6 highlights the 
hybridization of organic and inorganic components for the synthesis of ionic cocrystals 
and is exemplified by considering lithium salts with achiral and homochiral amino acids 
for the generation of 1:1 and 1:2 cocrystals. 
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CHAPTER 1 
Supramolecular synthon approach in the design of cocrystals 
 
1.1 Introduction 
The crystal engineering
1
 paradigm
 
 allows for the design and remodel of solid materials 
with desired physicochemical properties by utilizing non-covalent bonding. Crystal 
engineering relies on the basic principles of supramolecular chemistry, chemistry beyond 
the molecule, in developing novel entities by manipulating the non-covalent 
intermolecular interactions.
2
 Hydrogen bonding, metal coordination, van der Waals 
forces, hydrophobic forces, electrostatic effects and pi-pi interactions are some of the 
interactions which are commonly encountered in this regard. Many of the biological 
molecules are inherently sustained by molecular self-assemblies which are directed by 
non-covalent interactions. Naturally occurring nucleic acids such as DNA/RNA are held 
together by hydrogen bonds which clearly demonstrate how wide spread non-covalent 
interactions truly are.  
 Although the concepts of crystal engineering were introduced by Pepinsky
3
 in 1955, 
it was extensively utilized by Schmidt during photodimerization reactions of cinnamic 
acid in the solid state.
4
 During the 1990’s, the growth of crystal engineering gained a 
rapid momentum especially in the field of organic solids, metal-organic solids, 
organometallic
5
 and inorganic structures.
6
 More recently, crystal engineering principles 
have also been extended to pharmaceuticals.(need reference) Crystal engineering has 
2 
 
been defined in the late 1980’s by Gautam Desiraju as “the understanding of 
intermolecular interactions in the context of crystal packing and in the utilization of such 
understanding in the design of new solids with desired physical and chemical 
properties”.1 The basic crystal engineering approach involves first an understanding of 
how molecules interact with other molecules via intermolecular interactions and 
subsequently designing a supramolecular strategy for the synthesis of novel materials 
with desired properties and architecture.
7
 The concepts of crystal engineering can be 
applied to various fields such as coordination polymers
8
, nanotechnology
9
, porous 
materials for hydrogen gas storage
10,11
, non-linear optics (NLO)
12
, photographic 
materials
13
, polymorphism
14
, chiral resolutions
15
, purification, discovering new 
supramolecular synthons
9(a),16,17,18
 and even pharmaceutics
19
. 
The work presented herein focuses upon crystal engineering of multiple-component 
crystals with an emphasis upon the exploration of cocrystals in the context of delineation 
of the reliability of hydrogen bonded supramolecular synthons and their hierarchies. 
1.2  Supramolecular synthons 
The term synthon was coined by Corey in the context of organic chemistry and defined as 
“a structural unit within a molecule which is related to a possible synthetic operation”.20 
The word was later used to describe a synthetic building block rather than retrosynthetic 
fragmentation structures.
21
 In resemblance to this, Etter and Desiraju introduced graph 
sets
22
 and supramolecular synthons
1(b)
 respectively.  
Etter’s graph sets were based on the graph theory for classifying hydrogen bonds 
patterns into simpler notations. A graph set is denoted as   
 (r) where ‘G’ is a pattern 
designator, ‘r’ is its degree, ‘d’ denotes the number of donors and ‘a’ the number of 
3 
 
acceptors. The pattern designator has four different assignments: S, C, R and D based on 
whether hydrogen bonds are inter- or intramolecular. S (self) denotes an intramolecular 
hydrogen bond whereas for intermolecular bonds, C refers to hydrogen-bonded infinite 
chains, R refers to rings and D refers to non-cyclic dimers and other finite hydrogen 
bonded sets. However, the representation of a particular interaction between two 
functionalities using graph set notation does not provide complete information about the 
type of H-bond acceptors and donors. For example an acid dimer (homosynthon) and the 
acid-amide dimer (heterosynthon) are represented using   
 (8) graph set notation but, the 
representation does not reveal that whether the H-bond motif is a result of interaction 
between two different or same functionalities. This problem could be resolved using 
supramolecular synthons. Supramolecular synthons are defined as “structural units within 
supermolecules which can be formed and/or assembled by known or conceivable 
intermolecular interactions”. Supramolecular synthons are further categorized into (a) 
supramolecular homosynthon: composed of identical self-complementary functionalities 
or (b) supramolecular heterosynthon: composed of different but complementary 
functionalities.
23,24 
Generally, single-component or compounds containing the functional 
groups can be sustained by supramolecular homosynthons
25,26,27
 whereas; supramolecular 
heterosynthons
28,29,30
 can dominate in the presence of other competing functional groups. 
Figure 1.1 (a) illustrates the supramolecular homosynthon formed by the self-assembly of 
amide functionality, whereas Figure 1.1 (b) the supramolecular heterosynthon formed by 
the carboxylic acid and Narom. 
4 
 
(a)     (b)    
Figure 1.1 (a) Supramolecular homosynthon; (b) Supramolecular heterosynthon. 
1.3 CSD - A useful tool for cocrystal design 
The very first step in any crystal engineering experiment is to analyze existing crystal 
structures which can be carried out efficiently by the Cambridge Structural Database 
(CSD).
31
 The CSD is a repository for small molecule crystal structures of organic and 
organometallic compounds. It is a powerful tool which aids in the identification of robust, 
reliable synthons and also provides an opportunity to discover new and potential 
supramolecular synthons. But, there are situations when the CSD does not have sufficient 
information regarding the persistency of an underexplored or a new supramolecular 
synthon. In this case, a systematic study of the intermolecular interactions occurring in 
the related structures archived in the CSD coupled with experiments could possibly 
address the issue. But, there is high degree of reliability and plenty of information 
regarding many persistent supramolecular synthons
35-43
 which could be utilized in crystal 
engineering experiments. The reliability of CSD in designing a crystal engineering 
experiment was rightly quoted by Allen and Kennard as:  
‘‘the systematic analysis of large numbers of related structures is a powerful 
research technique, capable of yielding results that could not be obtained by any other 
method.’’32  
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The physicochemical properties of compounds inherently depend on the 
arrangement of molecules in the crystal structure and thus by pre-designing the 
arrangement of these molecules, the properties can be tailored. Especially, pre-designing 
the arrangement of molecules in multi-component crystals via supramolecular synthons 
when there are two or more than two different components is quite challenging. In this 
context utilization of the CSD in generating multi-component systems, namely cocrystals, 
is of great importance. However, the statistics obtained from the CSD cannot rule out the 
possibility of unexplored supramolecular synthons which are persistent enough to be 
considered as robust supramolecular synthons. Thus, the reserve of information in the 
CSD coupled with systematic experimental study could be utilized in addressing the 
hierarchy of supramolecular heterosynthons in the context of cocrystals.  
1.4 Design of cocrystals 
A detailed understanding of the supramolecular chemistry of the hydrogen bond acceptor 
and donor moieties in a given molecule and the selection of compounds (cocrystal 
formers) that are capable of forming complementary hydrogen bonds with a given 
molecule play an important role in the synthesis of cocrystals. Since cocrystals are multi-
component crystals overcoming the intermolecular interactions of the individual starting 
components (e.g. A
…
A, B
…
B). Stronger hydrogen bonds that form between the individual 
components (A
…
B) dictate the formation of the cocrystal. According to Fabian: 
“it is important to note that the formation of a supramolecular synthon is dictated by the 
strength of hydrogen bond formed between the given molecule and the cocrystal former 
rather than the number of hydrogen bond acceptors or donors present”.33 
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But, this does not mean that cocrystals with supramolecular homosynthons do not 
exist. Consequently, two different approaches could be utilized for the design of 
cocrystals. The first approach is breaking of the supramolecular homosynthon by utilizing 
a robust supramolecular heterosynthon (Figure 1.2 (a)).
34
 The second approach involves 
the use of the peripheral H-bond donors/acceptors wherein the cocrystal is sustained by 
supramolecular homosynthon as well as the heterosynthon (Figure 1.2 (b)).  
 
(a)      
(b)  
Figure 1.2 (a) Supramolecular heterosynthon formed in cocrystal UNIBAU (b) Supramolecular 
homosynthon and heterosynthon formed in cocrystal UNIZAO. 
 
 
Several systematic studies utilized the first approach which includes supramolecular 
heterosynthons hydroxyl-pyridine,
35
 aminopyridinium-carboxylate,
36
 pyridine-acid,
37,38
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amide-acid,
39,40,41
 acid-chloride,
42
 and carboxylates-weakly acidic hydroxyl moieties
43
 
have been conducted in detail to examine the reliability of the synthon in cocrystal 
design. This chapter in particular focuses on key supramolecular synthons formed by the 
functionalities present in p-coumaric acid, hydrochlorothiazide and polyphenols with 
other functionalities to determine the reliability and robustness of the synthon. 
1.5  CSD analysis 
1.5.1 General CSD Data Tables: The data tables were generated by using Conquest 
version 1.14 (Feb 2012 update) of 2012 release of CSD. During the searches the 
following constraints were applied: only organics, no ions (for synthons not involving 
ionic moieties), 3D coordinates, not disordered, no errors. Initial contact distances used to 
generate the histograms for each supramolecular synthon were well beyond the sum of 
the van der Waals radii of the hydrogen bond donor and the acceptor atom.  
 
 
 
Figure 1.3 Histogram for (acid) H-O···Narom supramolecular heterosynthon. 
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The cut-off ranges for the H-bond distances were determined by looking at the H-bond 
interactions in the structures from the histogram (Figure 1.3). Two searches were 
conducted namely (a) raw and (b) refined for every supramolecular synthon. The raw 
search was carried out between two functional groups in the presence of other competing 
functionalities whereas the refined search was done in the absence of other competing 
functionalities.  
Tables 1.1, 1.2, 1.3, 1.4 and 1.5 list the statistics obtained from the CSD for 
various supramolecular synthons for carboxylic acid (COOH), phenolic hydroxyl (Ph-
OH), 1
o
 & 2
o
 sulfonamides (SO2NHR) and 2
o
 phenyl amine (PhNHR) moieties with 
other functionalities such as six membered aromatic nitrogen (Narom), 1
o
 & 2
o
 amide 
(CONHR), 1
o
 & 2
o
 amine (NHR), carbonyl (C=O),  ethers (C-O-C), cyano (CN), nitro 
(NO2), chloride (Cl-), carboxylate (COO
-
) and water (H2O). The CSD analysis is 
confined to certain functional groups which belong to certain target compounds that have 
been a part of study in the later chapters of this dissertation. 
The terms which have been used in the tables are as follows:  
Example: Search for functional moiety X.  
(i) Pro-synthon (Y)  = the other functional moiety  
(ii) # both = No. of hits that contain both the functional groups X & Y;  
(iii) With “biological activity” or “drug” = No. of hits with which have any kind of 
biological activity (therapeutic activity) or is a medicinal drug 
(iv) # Hetero = No. of hits that form the supramolecular heterosynthon between 
the functional groups, X···Y;  
(v) # Homo = No. of hits that form the supramolecular homosynthon, X···X;  
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(vi) # Pro-synthon = No. of hits that form the supramolecular homosynthon Y···Y;  
(vii) Hetero exclusive = No. of hits that form the supramolecular heterosynthon 
between the functional groups, X···Y, in the absence of other functional 
groups;  
(viii) Range (Å) = H-bond cut off between X and Y supramolecular heterosynthon;  
(ix) Mean (Å, σ) = Average H-bond distance for the X···Y supramolecular hetero 
synthon with estimated standard deviation for the H-bond distance;  
(x) Cocrystals = No. of cocrystals which are sustained by the X···Y 
supramolecular heterosynthon. 
1.6 Discussion: 
The statistics obtained from the CSD mining listed in Tables 1.1 to 1.5 represent the 
frequency of a particular supramolecular synthon occurring between two functional 
moieties along with the range and the mean of H-bond distance. There are around 11,000 
hits that contain a carboxylic acid moiety. From the Table 1.1 of all the supramolecular 
synthons the frequency of occurrence of COOH∙∙∙Narom heterosynthon is highest when 
compared to other synthons. The refined search reveals that the COOH∙∙∙Cl 
supramolecular heterosynthon is 100% and the COOH∙∙∙Narom supramolecular 
heterosynthon occurs at ca. 92%. The percentage of occurrence of a hydrogen between 
COOH and 1
o
 amide functionality is ca. 90% while the O-H∙∙∙C=O supramolecular 
synthon is 82%. From the CSD statistics it was also found that when a raw search was 
conducted for COOH and 1
o
 sulfonamide moieties, the acid homosynthon dimer was 
found to occur at ca. 50% of the time.  From a search containing COOH and CN 
moieties, the COOH∙∙∙Narom was found to occur at ca. 48% of the time even in the 
10 
 
presence of other functional groups. Interactions between a COOH and water molecules 
were also analyzed using the CSD. The statistics reveal that in the refined search the 
probability of formation of C=O∙∙∙O-H supramolecular heterosynthon between acid 
functionality and water molecule was found to be 82%.  Of the total 11,000 hits for 
carboxylic acids there are about ca. 670 cocrystals exhibit the robust COOH∙∙∙Narom 
supramolecular heterosynthon.  Altogether, from the Table 1.1 it is clear that the 
functionalities such as Narom, amides (1
o
), Cl
-
 and carbonyls stand out as complimentary 
functionalities to CO, amenable to supramolecular heterosynthon formation. 
 Table 1.2 represents the CSD statistics obtained for the supramolecular 
interactions between O-H (phenolic) with other functionalities. There are about 11,500 
hits containing a phenolic moiety indicating the pervasive nature of this function group 
amongst organic compounds From the refined searches it was found that phenolic O-H 
has a higher tendency to form a heterosynthon with a carbonyl functionality (100%) 
within the H-bond range from 2.53-2.96 Å. Similarly, the percentage of forming an H-
bond between O-H and a carboxylate was also found to be 100%. The other 
functionalities which formed supramolecular heterosynthons at higher percentages are 1
o
 
amine (90%), Cl
-
 (88%), cyano (86%), Narom (82%) and 1
o
 amide (76%). Interestingly, 
there is only around 58% of a chance for the formation of O-H∙∙∙O-H between phenols 
and water molecules.  From the CSD analysis it is therefore clear that phenolic 
compounds hold a potential to be used as a cocrystal former for general purposes as they 
are capable of forming supramolecular heterosynthons with various functionalities.  
 The third category which includes the interactions between 1
o
 sulfonamide and 
other functionalities is tabulated in Table 1.3. Around 130 of 231 hits (56%) containing 
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the 1
o
 sulfonamide functionality were either drugs or hits possessing biological activity. 
Interestingly, there were very few entries that contained the 1
o
 sulfonamide moiety and 
one additional moeity. For example, there were only 4 hits which contain a 1
o
 
sulfonamide and Cl
-
 functionality three of which exhibited the N-H∙∙∙Cl supramolecular 
heterosynthon (75%). Similarly, there was just one hit containing the 1
o
 sulfonamide with 
the carboxylic acid functionality that exhibited the N-H∙∙∙C=O heterosynthon (100%). 
Nevertheless, when a raw search of 1
o
 sulfonamide with other functionalities was 
conducted the supramolecular heterosynthons had a much greater percentage of 
occurrences. There are only three hits containing a 1
o
 sulfonamide and a cyano group and 
even in the presence of other competing functional moieties all of the entries form the N-
H∙∙∙CN synthon. Likewise, around 89% of the hits containing 1o sulfonamide and Cl- 
functionality interact via N-H∙∙∙Cl- supramolecular heterosynthon whereas with 
functionalities such as esters, Narom and amines the frequency of forming a H-bond with 
1
o
 sulfonamide are 63%, 55% and 51%, respectively.  
 A CSD analysis for 2
o
 sulfonamide with different functionalities is presented in 
the Table 1.4. There are around 1,700 hits that contain the 2
o
 sulfonamide functionality 
and, similar to that of 1
o
 sulfonamide, the number of entries that contain various 
supramolecular heterosynthons in a refined search are minimal. In a refined search there 
is around a 73% chance of formation of a supramolecular heterosynthon between 2
o
 
sulfonamide and an amide. During the analysis it was found that there is just one hit of   
2
o
 sulfonamide with 1
o
 amide, Cl
-
 and COO
- 
functionalities respectively and each of the 
entry forms a supramolecular heterosynthon with the sulfonamide functionality. But, 
from this we cannot conclude that there is a 100% chance for the formation of a 
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heterosynthon between 2
o
 sulfonamide and 1
o
 amide, Cl
-
 and COO
-
 respectively. Thus 
sometimes due to insufficient data in the CSD for some of the supramolecular 
heterosynthons, the persistency cannot be determined. The interactions between a 2
o
 
sulfonamide with 1
o
 and 2
o
 amines occurs at higher frequencies (80% and 89% 
respectively) in the presence of other moieties. The other functionalities which exhibit a 
ca. 50% chance for the formation of supramolecular heterosynthon with 2
o
 sulfonamide 
are 2
o
 amide (61%), Narom (56%) and carbonyl groups (45%). 
  The CSD analysis for PhNHR reveals that there are about 3818 hits, of which 
10% hits are either drugs or have biological activity. From Table 1.5 it is evident that 
supramolecular heterosynthons occur at a higher frequency in a refined search when 
compared to that of a raw search. The functional moieties which are capable of forming a 
hydrogen bond with PhNHR at a frequency greater than 50% are Cl
-
 (67%), amide 
(62%), carbonyl (59%), phenolic O-H (56%) and cyano (53%). The CSD data also 
revealed that the number of cocrystals containing the PhNHR moiety is very low when 
compared to other moieties. The statistics obtained from the CSD could in turn be 
utilized in designing a crystal engineering experiment for the synthesis of multi-
component crystals.  
1.7  Summary 
Cocrystals represent novel materials with many practical applications and are one of the 
important outcomes of crystal engineering.  The rational design and synthesis of 
cocrystals can be pursued with a systematic study by selecting appropriate cocrystal 
former based on the persistency of supramolecular synthons that both of the components 
are capable of forming. The CSD stands out as a priceless and invaluable tool which 
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provides enormous information pertaining to the crystal structure analysis. The CSD data 
table enlisted represents how frequently the supramolecular synthon occurs between two 
functionalities within the specific range of H-bond distance. Furthermore, the information 
could also be utilized for the selection of appropriate cocrystal formers for the synthesis 
of cocrystals. The later chapters of this dissertation emphasize the exploration of new but, 
robust and persistent supramolecular synthons in the context of crystal engineering of 
cocrystals. 
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CHAPTER 2 
Hierarchy of supramolecular synthons: persistent hydrogen bonds between 
carboxylates and weakly acidic hydroxyl moieties in cocrystals of zwitterions 
 
 “Reprinted (adapted) with permission from (Crystal Growth & Design, 2010, 10 (8), 
3568–3584). Copyright (2010) American Chemical Society.” 
The link to the publication is http://pubs.acs.org/doi/pdf/10.1021/cg100484a 
Please refer to the Appendix 1 of this dissertation for the full article. 
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CHAPTER 3 
Hierarchy of Supramolecular Synthons: Supramolecular Homosynthons vs. 
Supramolecular Heterosynthons in Cocrystals of Catechols 
 
3.1 Introduction 
Cocrystals, a long known
1,2 
which were relatively little studied until last decade, 
are of topical interest because active pharmaceutical ingredients, APIs, are predisposed to 
form cocrystals with pharmaceutically acceptable cocrystal formers such as carboxylic 
acids. The fact that pharmaceutical cocrystals can profoundly impact clinically important 
properties of APIs such as aqueous solubility and crystal form stability justifies the 
continued study of pharmaceutical cocrystals.  However, the driving force for the 
formation of pharmaceutical cocrystals is molecular recognition between the cocrystal 
formers and as such they represent a class of compound that exemplifies how crystal 
engineering
3,4,5,6
 can exploit supramolecular synthons
7
 for the design of new solids with 
desired physicochemical properties.
8
  Simply put, if a persistent supramolecular 
heterosynthon between different but complementary functional groups occurs in favor of 
a competing supramolecular homosynthon between identical functional groups, then a 
cocrystal can be anticipated for a particular pair of cocrystal formers.
9
 In such a context, 
supramolecular heterosynthons such as acid-pyridine,10 acid-amide,11,12 hydroxyl-
amine,
13
 hydroxyl-pyridine,13(b),15(e),14,15 aminopyridinium-carboxylate,16 carboxylate-
hydroxyl (weakly acidic)
17
 represent persistent supramolecular heterosynthons of the type 
27 
 
that can be reliably and readily exploited to prepare new classes of multi-component 
solid.  They also provide broad and fundamental insight into molecular recognition 
processes. 
In such a context, the Cambridge Structural Database (CSD)
18
 is a powerful tool 
that can provide information concerning the reliability and robustness of supramolecular 
synthons but only if there are sufficient entries for a given class of compound.  The CSD 
can thereby afford hierarchal information about the relative strengths of competing 
supramolecular synthons, including the hierarchy of supramolecular heterosynthons vs. 
any supramolecular homosynthons that might occur between the cocrystal formers. In 
addition, there are cocrystals reported in the literature where the target compounds are 
sustained by supramolecular homosynthons also in the presence of cocrystal formers.  
Cocrystals between two components containing same functionalities have also been 
designed and have been explored in carboxylic acid functionalities.  
The carboxylic acid dimers formed between two different carboxylic acids have 
been referred to as heterodimers and as such they date at least as far back as a study by 
Kendall in 1914.
19
 The Kendall study indicated that cocrystals will form between two 
carboxylic acids if their acidic strengths are sufficiently different. Later studies by Pinkus 
et al
20
 suggested that the substituents on the carboxylic acids also have an impact on the 
formation of heterodimers. According to this the carboxylic acids containing electron-
withdrawing groups are capable of forming heterodimers with systems containing 
electron-donating groups. Etter used heterodimers to effect solid-state nucleophilic 
substitution in cocrystals formed between two carboxylic acids (4-chloro-3, nitrobenzoic 
acid and 4-aminobenzoic acid)
21
 and most recently Seaton et al
22,23
 used the Hammett 
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substituent parameter (σ) to predict whether or not a cocrystal would result between the 
two different carboxylic acids. But, how common is the formation of supramolecular 
homosynthon when the components of a cocrystal have different moieties. 
           To address this issue we investigated the cocrystals of target compounds (in-
house) that contain a catechol moiety (two adjacent O-H functionalities on a benzene 
ring). The study would investigate how common is the catechol dimer during the 
cocrystal formation and how homosynthon competes with other heterosynthons. Figure 
3.1 represents the targeted catechols and the cocrystal formers studied herein. The 
phenolic O-H moiety is amphiprotic in nature i.e. it can simultaneously act as a proton 
acceptor as well as a donor and it is therefore self-complementary.  Furthermore, the pKa 
value of an unsubstituted phenol is ca. 10, which means that is unlikely to be 
deprotonated even by stronger organic bases.  It is therefore possible that phenols could 
be more generally used as cocrystal formers than carboxylic acids.   
 
Figure 3.1 Structures of targeted catechols (top two rows) and the cocrystal formers (bottom row). 
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We have previously addressed the hierarchy of phenols related to their utility as cocrystal 
formers
17
 and herein we focus upon catechol moieties as a model for nutraceutical 
cocrystal formers. Similarly, polyphenols including flavonoids which have attracted the 
attention of the scientific community are now also being recognized by the general public 
because of their life saving anti-oxidants. Moreover, these polyphenols are widely present 
in fruits, vegetables and beverages such as tea, coffee and wine. The availability of plenty 
of hydrogen bond donors/acceptors with many utilitarian values including health benefits 
suggests that polyphenols and flavonoids are worth studying from a crystal engineering 
perspective.  
3.2 Experimental: 
Nutraceutical compounds such as polyphenols and phenolic acids (Figure 3.1) were 
targeted for the present study: caffeic acid (CFA), ethyl gallate (EGL), methyl gallate 
(MGL), propyl gallate (PGL) and protocatechuic acid (PCA). Compounds such as: 3, 5 
dimethyl pyrazole (DMP), glycine anhydride (GAH), iso-nicotinamide (INM), isoniazid 
(INZ) and nicotinamide (NAM) were used as cocrystal formers. All reagents were 
obtained from commercial suppliers and used without further purification.   
3.2.1 Preparation of single crystals: Single crystals of 11 catechol cocrystals were 
obtained by dissolving the starting materials in appropriate solvent(s) followed by slow 
evaporation. All solvents were distilled prior to their use.  Specific experimental details 
are as follows: 
Caffeic acid•Glycine anhydride, CFAGAH: Caffeic acid, 18.0 mg (0.100 mmol) and 
glycine anhydride,  57.0 mg (0.500 mmol) were dissolved in 3 mL of 1:1 acetone/water 
mixture and heated until a clear solution was obtained. The solution was allowed to 
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evaporate at room temperature and colorless crystals of CFAGAH were harvested after 
two days (melting point = 221.7 
o
C).  
Caffeic acid•Isoniazid, CFAINZ: Caffeic acid, 18.0 mg (0.099 mmol) and isoniazid, 
28.0 mg (0.204 mmol) were mixed in 3 mL of  1:1 acetone/water mixture. The resulting 
solution was left for slow evaporation in the hood. Light yellow crystals of CFAINZ were 
harvested after three days (melting point = 185 
o
C). 
Caffeic acid•Isonicotinamide dihydrate, CFAINM•2H2O: Caffeic acid, 9 mg (0.100 
mmol) and isonicotinamide,  30 mg (0.500 mmol) were dissolved in 3 mL of 1:1 
methanol/water mixture by heating on a hotplate. The resulting solution was placed in the 
hood for slow evaporation. Yellow needle-like crystals were harvested after five days 
(melting point = 150.7 
o
C). 
Ethyl gallate•Glycine anhydride, EGLGAH: Ethyl gallate, 20.0 mg (0.101 mmol) and 
glycine anhydride, 12.00 mg (0.105 mmol) were mixed in 3 mL of  1:1 ethanol/water 
mixture. The resulting solution was left for slow evaporation in the hood. Crystals of 
EGLGAH were obtained after a week (melting point = 164.9 
o
C).  
Ethyl gallate•Isoniazid, EGLINZ: Ethyl gallate, 20.0 mg (0.101 mmol) and isoniazid, 
14.00 mg (0.102 mmol) were mixed in 3 mL of  1:1 acetone/water mixture. The resulting 
solution was left for slow evaporation in the hood. Colorless crystals of EGLINZ were 
harvested after two days (melting point = 94.0 
o
C). 
Ethyl gallate•3, 4 dimethyl pyrazole, EGLDMP: Ethyl gallate, 71.28 mg (0.359 mmol) 
and 3, 5-dimethylpyrazole, 35.40 mg (0.368 mmol) were mixed in 3 mL of 1:1 
ethanol/water mixture. The resulting solution was left for slow evaporation in the hood 
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which resulted in colorless crystals of EGLDMP after four days (melting point = 141.4 
o
C). 
Methyl gallate•Glycine anhydride, MGLGAH: Methyl gallate, 18.0 mg (0.098 mmol) 
and glycine anhydride, 12.0 mg (0.105 mmol) were mixed in 3 mL of  1:1 ethanol/water 
mixture. The resulting solution was left for slow evaporation in the hood. Crystals of 
MGLGAH were harvested after two days (melting point = 227.6 
o
C).  
Methyl gallate•Isoniazid, MGLINZ: Methyl gallate, 18.0 mg (0.098 mmol) and 
isoniazid, 14.00 mg (0.102 mmol) were mixed in 3 mL of  1:1 acetone/water mixture. 
The resulting solution was left for slow evaporation in the hood. Colorless crystals were 
harvested after five days (melting point = 194.3 
o
C). 
Protocatechuic acid•Glycine anhydride, PCAGAH: Protocatechuic acid, 15.00 mg 
(0.097 mmol) and glycine anhydride, 12.00 mg (0.105 mmol) were mixed in 3 mL of  1:1 
acetone/water mixture. The resulting solution was left for slow evaporation in the hood. 
Colorless crystals of PCAGAH were harvested after a week (melting point = 249.9 
o
C).  
Propyl gallate•3, 4 dimethyl pyrazole, PGLDMP: Propyl gallate, 21.0 mg (0.098 
mmol) and 3, 5-dimethylpyrazole, 19.0 mg (0.198 mmol) were mixed in 3 mL of 
methanol. The resulting solution was left for slow evaporation in the hood. Block like 
crystals of PGLDMP were harvested after three days (melting point = 130.8 
o
C).  
Propyl gallate•Glycine anhydride, PGLGAH•2H2O: Propyl gallate, 21.0 mg (0.098 
mmol) and glycine anhydride, 24.0 mg (0.210 mmol) were mixed in 3 mL of 
ethanol/water mixture. The resulting solution was left for slow evaporation in the hood. 
Block like crystals of PGLGAH•2H2O were harvested after three days (melting point = 
150.2 
o
C). 
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3.3 Characterization of cocrystals: 
3.3.1 Differential scanning calorimetry (DSC): Thermal analysis was performed on a 
TA Instruments DSC 2920 Differential Scanning Calorimeter. Aluminum pans were used 
for all samples and the instrument was calibrated using an indium standard. For 
reference, an empty pan sealed in the same way as the sample was used.  The samples 
were heated in the DSC cell using inert nitrogen conditions, from 30 °C to the required 
temperature (melting point of the cocrystal) at a rate of 10°C/min.  
3.3.2 Thermogravimetric analysis (TGA): A Perkin Elmer STA 6000 Simultaneous 
Thermal Analyzer was used to conduct thermogravimetric analysis. Open alumina 
crucibles were used to heat the samples from 30 °C to 400 °C at 10 °C/min scanning rate 
under nitrogen stream. 
3.3.3 Infrared spectroscopy (FT-IR): To characterize the cocrystals by infrared 
spectroscopy a Nicolet Avatar 320 FT-IR instrument was used. Sample amounts of 1-2 
mg were used and spectra were measured over the range of 4000–400cm-1 and analyzed 
using EZ Omnic software. 
3.3.4 Powder X-ray diffraction (PXRD): A Bruker AXS D8 powder diffractometer 
was used for all PXRD measurements with experimental parameters as follows: Cu Kα 
radiation (λ = 1.54056 Ǻ); 40 kV and 30 mA. Scanning interval: 3-40° 2θ; time per step: 
0.5 sec. The experimental PXRD patterns and calculated PXRD patterns from single 
crystal structures were compared to confirm the composition of bulk materials. 
3.3.5 Single-Crystal X-ray Data Collection and Structure Determinations: Crystals 
suitable for X-ray crystallography were selected using an optical microscope. Data for 
CFAGAH, CFAINZ, CFAINM•2H2O, EGLGAH, EGLINZ•2H2O, EGLDMP, 
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MGLGAH, MGLINZ, PCAGAH, PGLDMP and PGLGAH•2H2O were collected on 
Bruker-AXS SMART APEXII CCD diffractometer with monochromatized Cu Kα 
radiation (λ = 1.54178 Å) connected to a KRYO-FLEX low temperature device. Indexing 
was performed using SMART V5.625 
24(a)
 or using APEX 2008 V1-0.
34(b)
 Frames were 
integrated with Saint Plus 7.51
34(c)
 software package. Absorption correction was 
performed by multi-scan method implemented in SADABS.
34(d) 
The structures were 
solved using SHELXS-97 and refined using SHELXL-97 contained in SHELXTL 
V6.10
34(e) 
and WinGX V1.70.01
34(f,g,h)
 programs packages. All non-hydrogen atoms were 
refined anisotropically. Hydrogen atoms were placed in geometrically calculated 
positions or found in the Fourier difference map and included in the refinement process 
using riding model or without constraints. Crystallographic data and selected H-bond 
distances for the 15 cocrystals are presented in Tables 3.4 and 3.5. 
3.4 CSD analysis:  
In order to determine the occurrence of catechol supramolecular homosynthons for 
compounds containing catechol moiety a CSD v5.32 (Aug 2011 update) study was 
conducted. Since O-H moieties of the catechol could act as both acceptor as well as donor 
(amphiprotic) the O-H could lead to multiple interactions between themselves and with 
other functionalities. Therefore, it is important to understand the possible interactions that 
could take place among the catechols. Figure 3.3 represents the possible interactions that 
could occur between catechol moieties. The statistical data obtained from the CSD is 
tabulated in Table 3.1. All CSD searches were subjected to the following constraints: 3D 
coordinates present, only organics, no ions, and R ≤ 7.5% (entries containing salts, metals 
and duplicates are excluded). 
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Figure 3.2 Histograms of OH•••OH catechol supramolecular homosynthon search obtained from 
CSD. (CSD v5.32, Sep 2011 update) 
 
The histogram generated from the CSD search determines the bond distance range for the 
occurrence of O-H∙∙∙O-H supramolecular homosynthon as shown in Figure 3.2. The cut-
off ranges for the H-bond distances were determined by checking the structures and by 
analyzing the H-bond distances. The catechol moieties can interact with each other and 
lead to the formation of supramolecular homosynthon I, namely, catechol dimer or 
sometimes it may result in the formation of catemer between two catechol moieties, 
supramolecular synthon II. Supramolecular synthon III could occur between catechols 
when water is present in the crystal structure as represented in Figure 3.3. The hydrogen 
distances obtained from the histogram reveal that the supramolecular homosynthons I 
and II occur within the typical range of 2.685 – 3.02 Å (mean-2.818 (7) Å).  
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Figure 3.3 Possible supramolecular synthons that could occur between catechols. 
 
The raw statistics obtained from the CSD reveal the presence of 460 crystal structures 
that contain a catechol moiety.  Of which 97 (22%) entries are sustained by 
supramolecular homosynthon I (catechol dimer) whereas 145 (32%) hits are sustained by 
supramolecular synthon II. Hydrates are also present among the catechols and are 
observed in almost one-fourth of the total catechols. The supramolecular synthon III in 
which there are two water molecules inserted in the catechol dimer is exhibited by less 
than 5% of the total hits and 26% with supramolecular synthon IV where only one of the 
O-H functionality of the catechol moiety interacts with the water molecule. But when 
compared within catechol hydrates (Table 3.1), the frequency of supramolecular synthon 
IV is observed in almost 94% of hydrates. So far 62 cocrystals (24 cocrystal hydrates) 
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have been reported in the CSD that contain the catechol moiety of which only eight 
cocrystals (13%) are sustained by catechol dimer. 
Table 3.1: CSD statistics for Catechols. 
 
Raw Search: 
Total no. of hits with Catechol moiety 440 
No. of hits that form supramolecular synthon I (Catechol dimer) 97 / 440 (22.0%) 
No. of hits that form supramolecular synthon II  145 / 440 (31.5%) 
No. of hits that form supramolecular synthon III 19 / 440 (4.3%) 
No. of hits that form supramolecular synthon IV 113 / 440 (25.7%) 
 
No. of hits with Catechol + nH2O  120 / 440 (27.3%) 
No. of hits that form supramolecular synthon I (among catechol hydrates) 10 / 120 (8.3%) 
No. of hits that form supramolecular synthon II 24 / 120 (20%) 
No. of hits that form supramolecular synthon III 19 / 120 (15.8%) 
No. of hits that form supramolecular synthon IV 113 / 120 (94.2%) 
 
No. of cocrystals that have Catechol moiety 62 / 440 (14.1%) 
No. of cocrystals that form supramolecular synthon I 8 / 62 (12.9%) 
No. of hits that form supramolecular synthon II 11 / 62 (17.7%) 
No. of cocrystals that have Catechol moiety + nH2O 24 / 64 (37.8%) 
No. of hits that form supramolecular synthon III 1 / 24 (4.2%) 
No. of hits that form supramolecular synthon IV 23 / 24 (95.8%) 
Refined Search: 
Total no. of hits with Catechol moiety 13 
No. of hits that form supramolecular synthon I  8 (61.5%) 
No. of hits that form supramolecular synthon II (some hits also contain synthon I) 8 (61.5%) 
Constraints: Only organics, no ions, 3D coordinates, R ≤ 0.075, no duplicates 
 
Supramolecular synthons II, III and IV are exhibited by 18%, 2% and 37% respectively 
and in rest of the cocrystals the O-H moieties of the polyphenols are bonded to other 
functional groups. The refined search contains only thirteen entries containing catechol 
moiety where 62% of the crystal structures were found to contain supramolecular 
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synthons I and II.  There is just one cocrystal, NEZMAG
25
 (1,1-bis(4-Hydroxyphenyl) 
cyclohexane and catechol), in the refined search (no other functional groups than O-H 
moiety) which is sustained by a tetramer formed by two of each catechol (only one of the 
O-H) and 1,1-bis(4-Hydroxyphenyl) molecules. 
3.5. Description of the crystal structures 
3.5.1 CFAINM•2H2O: The cocrystallization of CFA and INM resulted in the 
formation of a dihydrate of the cocrystal. The CFA molecules are disordered in the 
cocrystal. A catechol dimer (supramolecular homosynthon-I) was not observed in the 
CFA molecules but instead there is an insertion of four water molecules between the two 
CFA molecules preventing them from forming the dimer. The insertion of water 
molecules results in 3+3 hexameric unit. The acid moiety of CFA molecule donates a 
hydrogen bond to the Narom moiety of INM molecule resulting the robust COOH···Narom 
hydrogen bond (2.733 (1) Å). The amide moieties if the INM molecules engage 
themselves in formation of amide dimer with hydrogen bond distance between N-H···O 
equal to 2.941 (2) Å. The interactions between the CFA, water and the INM molecules 
thereby results in the generation of a linear tape and these tapes are sandwiched by 
adjacent tapes. 
 
Figure 3.4 Illustration of intermolecular hydrogen bonding in CFAINM•2H2O (The CAF molecules 
are disordered in the cocrystal). 
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Each tape interacts with the adjacent tapes through: (a) the O-H of the acid moiety of 
CFA molecules with one water molecule; (b) the anti-hydrogen of the amide functionality 
INM the molecules hydrogen bond to the carbonyl moiety of CFA molecules 
respectively. The hydrogen bond distances observed for O-H···O and N-H···O 
interactions are 2.830 (3) Å and 3.005 (2) Å respectively. Overall hydrogen bonding is 
illustrated in Figure 3.4. 
3.5.2 CFAINZ: The CFAINZ cocrystal crystallizes in centro-symmetric space group 
(P-1) with one molecule of CFA and INZ in the asymmetric unit. The cocrystal is 
sustained by the supramolecular synthon I (Figure 3.5). The hydrogen bond distance 
between O∙∙∙O-H for the supramolecular synthon I is 2.753(2) Å which falls within the 
range generated by the histogram for O-H···O-H interactions.  
 
Figure 3.5 Illustration of supramolecular sheet generated by the intermolecular interactions in 
CFAINZ. 
The INZ molecules hydrogen bond to the catechol dimer peripherally with the anti-
hydrogens of the hydroxyl moieties (O···O: 2.671() Å, O···N: 2.976 () Å). Whereas the 
acid moiety of CFA molecules hydrogen bond to the Narom of the INZ molecules through 
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the robust supramolecular heterosynthon O···Narom (O
…
N: 2.618 () Å) thereby resulting 
in the formation of linear tapes. The O···Narom supramolecular heterosynthon formed 
between the CFA and INZ molecules follows the hierarchy for the intermolecular 
interactions between the carboxylic acids and Narom.
23(b)
 The tapes in CFAINZ are linked 
to each other laterally through the interactions between the carbonyl of CFA and the anti-
hydrogens of the hydrazine moieties (O···N (2.886() Å) leading to the formation of a 
supramolecular sheet as represented in Figure 3.5.  
3.5.3 CFAGAH: The 1:1 cocrystal of CFAGAH did not contain any of the synthons as 
proposed in Scheme 1 rather the cocrystal is stabilized by the tapes of GAH dimers 
(O···N: 2.892 (2), 2.916 (2) Å). The supramolecular homosynthon (dimers) formed 
between the amide functionalities of two GAH molecules can be represented by graph set 
notation
26
   
  (8). Similar kinds of dimers are also observed in the pure crystal structure 
of GAH with hydrogen bond distance of 2.84 Å. The tapes of GAH dimers hydrogen 
bond to one of the O-H and the acid moieties of the CFA molecules on either side 
through O···O-H: 2.722 (2) Å and O···O-H: 2.650 (1) Å) respectively.  
(a)  
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(b)  
 
Figure 3.6 (a) Representation of hydrogen bonding in CFAGAH; (b) CFA dimer as observed in 
CFAGAH. 
 
The other O-H and the carbonyl moieties of CFA molecules engage themselves in the 
formation of dimers as represented in Figure 3.6 (b) but, this kind of dimer formation is 
not observed in the pure crystals structure of CFA molecules. Whereas, the CFA 
molecules are exist as acid dimers and the interactions between the O-H moieties. Overall 
hydrogen bonding is shown in Figure 3.6 (a). Twelve cocrystals of GAH have been 
reported to date in the CSD of which five cocrystals are sustained by GAH dimers as 
observed in CFAGAH. 
3.5.4 EGLDMP: The cocrystallization of EGL and DMP resulted in the formation of a 
1:1 cocrystal in centro-symmetric space group (P-1) with one molecule of each in the 
asymmetric unit. In EGLDMP the catechol moieties of EGL molecules interact with 
each other through supramolecular homosynthon I with hydrogen bond distance of 2.654 
(2) Å which can be described by   
 (10) graph set as shown in Figure 3.7 (a). Two DMP 
molecules hydrogen bond on either side of synthon I via O-H···N and O···N-H hydrogen 
bonds (O-H···N: 2.705 (2) Å; O···N: 2.832 (2) Å) thereby generating a supramolecular 
sheet. Thus the overall hydrogen bonding results in the generation of sheets in the form of 
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bilayers which stack in ABAB fashion stabilized by weak π-π interactions as represented 
in Figure 3.7 (b). The EGL molecule in the cocrystal is observed to be flat with all the O-
H moieties lying on the plane.   
 
(a) 
 
(b) 
Figure 3.7 (a) Generation of supramolecular sheet in EGLDMP; (b) Stacking of bilayers in ABAB 
fashion. 
 
The only cocrystal of EGL reported in the CSD (PIJHIA)
27
 with 2-(6-diethylamino-3-
diethyliminio-3Hxanthene- 9-yl) benzoate (rhodamine B base-RBB) is sustained by 
charge assisted 2-point hydrogen bond (COO
-
···O-H ) between the carboxylate and the 
O-H moieties. One of the O-H moieties of the EGL molecule in the cocrystals is out of 
the plane by 67.82
o
 whereas in EGLDMP all the O-H moieties are planar. 
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3.5.5 EGLGAH: The 2:1 EGLGAH cocrystal is sustained by supramolecular synthon 
I via O-H∙∙∙O hydrogen bond (2.707 () Å and 2.705 () Å) with two of the O-H moieties of 
the EGL molecule involved in the dimer formation. The intermolecular hydrogen bond 
distances of the supramolecular I are within anticipated range obtained from the CSD 
(2.685 – 2.968 Å).  
 
Figure 3.8 Intermolecular hydrogen bonding in EGLGAH. 
The GAH dimer no longer exists in the cocrystal as they did in CFAGAH. The amide 
moiety of GAH molecules laterally connect the catechol dimers through O-H∙∙∙O (2.678 
() Å) and O-H∙∙∙N-H (2.950 () Å) H-bonds thereby generating a linear tape. These tapes 
are connected to the adjacent tapes through EGL dimers described by   
  (14) graph set 
as illustrated in Figure 3.8 and results in the formation of corrugated sheet. The dimer is 
formed between the O-H and C=O moieties of two EGL molecules via O-H∙∙∙O (2.739 () 
Å and 2.738 () Å) hydrogen bonds. The EGL molecule in the cocrystal is not planar 
whereas the dihedral angle between the aliphatic chain and the gallate ring is 79.64
o
. The 
43 
 
supramolecular corrugated sheets form layers stacked one above the other as presented in 
Figure 3.9.  
 
Figure 3.9 Illustration of stacking of supramolecular layers. 
3.5.6 EGLINZ•2H2O: The cocrystallization of EGL and INZ result in the formation of 
the dihydrate of the cocrystal. There are three EGL, two INZ and two water molecules in 
the asymmetric unit. Synthon III is observed rather than synthon I in the cocrystal with 
the unexpected presence of water in the crystal structure. The serendipitous formation of 
the dihydrate illustrates the unpredictable nature of water in crystal engineering 
experiments.
28
  One of the water is trifurcated between other two EGL molecules through 
O-H∙∙∙O hydrogen bonds (2.719 () Å, 2.969 () Å, 2.972 () Å) and connect the O-H 
moieties of two EGL molecules whereas the other water molecules connects the N-H 
moiety of the INZ and the O-H moiety of the remaining EGL molecule through N-H∙∙∙O 
(2.837 () Å) and O-H∙∙∙O (2.726 () Å) hydrogen bond. The O-H moieties of these two 
EGL molecules hydrogen bond to the Narom of the INZ molecules thus forming the robust 
O-H∙∙∙Narom (2.69 () Å, 2.632 () Å) supramolecular heterosynthon.
14(b)
 The overall 
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hydrogen bonding results in the formation of a supramolecular sheet, represented in 
Figure 3.10. Unlike in EGLGAH, the EGL molecules in EGLINZ•2H2O are planar in 
the cocrystal. 
 
Figure 3.10 Hydrogen bonding in EGLINZ•2H2O. 
3.5.7 MGLGAH: The cocrystallization between MGL and GAH results in the 
formation of 2:1 molecular complex in monoclinic space group (C2/c). The MGLGAH 
cocrystal is also sustained by supramolecular synthon I with the hydrogen bond distance 
between O-H∙∙∙O of 2.720 (2) Å 
 
Figure 3.11 Illustration of twisted catechol dimer in MGLGAH. 
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. The catechol dimer unlike in other cocrystals is not planar and is twisted by a dihedral 
angle of 53.23
o
 as presented in Figure 3.11. In all the GAH cocrystals (which are 
sustained by catechol dimers) discussed so far, GAH forms a tetrameric unit by hydrogen 
bonding itself on the either side of the catechol dimer but in MGLGAH it is not so. 
Instead, each the N-H moieties of the GAH molecules forms bifurcated hydrogen bonds 
with two hydroxyl moieties of two different MGL molecules thereby connecting two 
catechol dimers. The N-H∙∙∙O hydrogen bond distances are 2.999 (2) Å and 3.060 (2) Å 
as represented in Figure 3.12 (a). 
(a)  
                                                                                                   
                             (b)  
Figure 3.12 Hydrogen bonding environment around GAH molecules (a) involving N-H moiety (b) 
involving C=O moiety in MGLGAH. 
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Similarly the carbonyl moieties of GAH molecules are also hydrogen bonded to another 
catechol dimer via C=O∙∙∙O-H hydrogen bonds (2.688 (2) Å as shown if Figure 3.12 (b). 
The overall hydrogen bonding in MGLGAH results in the formation of a 3-D network as 
shown in Figure 3.13. 
 
Figure 3.13 Overall hydrogen bonding in MGLGAH. 
 
3.5.8 MGLINZ: The crystals structure of MGLINZ reveals the presence of two 
independent MGL and one INZ molecules in the asymmetric unit. Supramolecular 
homosynthon I is present in the cocrystal in which one of the independent MGL molecule 
participates in the dimer formation. The hydrogen bond distances observed for the 
catechol dimer in MGLINZ are 2.915 (3) Å (O-H∙∙∙O). The hydrazine moieties INZ 
molecules hydrogen bond to the peripherals of the catechol dimer via N-H∙∙∙O (2.680 (3) 
Å and 2.953 (3) Å) hydrogen bonds similar to that found in the cocrystals CFAINZ and 
GALINZ (reported elsewhere). The second independent MGL molecule interacts with 
INZ and other independent MGL molecules by donating two hydrogen bonds to Narom 
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(O-H∙∙∙Narom) and the carbonyl moieties (O-H∙∙∙O) and the hydrogen bonds for these 
interactions are 2.661 (3) Å and 2.689 (3) Å  respectively.  Overall crystal packing in 
MGLINZ is presented in Figure 3.14. 
 
Figure 3.14 Crystal packing of 2:1 MGLINZ cocrystal.  
3.5.9 PCAGAH:  The 1:1 complex between PCA and GAH does not exhibit any of the 
supramolecular synthons mentioned in scheme 1. The supramolecular homosynthons 
sustained by GAH dominates the other hydrogen bonds in the crystal structure. The 
hydrogen bond distances for the GAH dimers (N-H∙∙∙O: 2.941 (2) Å) are greater than 
what is observed in the pure crystal structure of GAH (N-H∙∙∙O: 2.851 Å). Through out 
the crystal structure of PCAGAH the GAH molecules exists as dimers which are 
connected to other dimers via C=O∙∙∙N-H (2.947 (2) Å) hydrogen bonds. The one of the 
carbonyl moieties of GAH molecule forms a bi-furcated hydrogen bond with one of the 
O-H moieties of thePCA molecules generating a tape as presented in Figure 3.15 (a). The 
remaining O-H of each PCA molecule donates a hydrogen bond to the carbonyl moiety 
(O-H∙∙∙C=O: 2.721 (2) Å) of the acid group of neighboring PCA molecule as shown in 
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Figure 3.15 (b) (GAH molecules are removed for clarity) thus generating anti-parallel 
tapes of PCA molecules.  
 
(a) 
(b)  
(c)  
Figure 3.15 (a) Illustration of tape generated by the H-bonding between PCA and GAH molecules; 
(b) Interactions occurring between PCA molecules; (c) Interactions occurring between GAH 
molecules. 
 
Likewise the GAH molecules hydrogen bond to other GAH molecules to form dimers 
with a hydrogen bond distance of 2.941 (2) Å and these dimers are connected to other 
dimers via N-H∙∙∙C=O bonds (2.947 (2) Å) as represented in Figure 3.15 (c). The 
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hydrogen bond distance observed is greater than what is observed in pure GAH crystal 
structure (PCA molecules are not shown for clarity). The overall hydrogen bonding 
results in the formation of 3-D network as illustrated in Figure 3.16. 
 
Figure 3.16 Illustration 3-D network resulted in PCAGAH cocrystal viewed along x-axis. 
3.5.10 PGLDMP: The crystal structure of PGLDMP reveals that the PGL and DMP 
molecules form a 1:1 complex. The cocrystal is sustained supramolecular homosynthon I 
through strong O-H∙∙∙O (2.664 (2) Å) hydrogen bonds. The DMP molecules hydrogen 
bond to the catechol dimer (Figure 3.17) through Narom∙∙∙O-H and N-H∙∙∙O hydrogen 
bonds (2.689 (2) Å and 2.818 (2) Å) similar to that observed in cocrystals EGLDMP and 
GALDMP
32
. The molecular assembly which is formed between two each of PGL and 
DMP molecules interacts with four neighboring assemblies.  The interactions take place 
between third O-H of the PGL and the carbonyl moieties (O-H∙∙∙O: 2.687 (2) Å) of PGL 
molecules as presented in Figure 3.18. The tetrameric assemblies are found to be planar 
in EGL and PGL whereas in GALDMP, the DMP molecules are out of plane containing 
the catechol dimer with a dihedral angle of 44.51
o
. 
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Figure 3.17 Illustration of catechol supramolecular homosynthon (synthon-I) in PGLDMP. 
 
Figure 3.18 Interactions of the molecular assemblies formed in PGLDMP.  
3.5.11 PGLGAH•2H2O: The cocrystal crystallizes in monoclinic space group (P21/c) 
with the asymmetric unit consisting of two independent PGL molecules, two water 
molecules and one GAH molecules. The supramolecular synthon I was expected in the 
cocrystal but due to the unexpected intrusion of water molecules in the crystal structure 
neither of the GAH dimers were observed. Each of the PGL molecule donates bi-furcated 
hydrogen bonds to the GAH molecule via O-H∙∙∙N-H (2.640 (2) Å) and O-H∙∙∙O (2.993 
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(2) Å) interactions. Likewise bifurcated bonds are formed by each water molecule with 
two of the O-H moieties of PGL molecules (O∙∙∙O-H: 2.781 (2) Å and 2.960 (2) Å) 
resulting in the formation of supramolecular synthon IV (Figure 3.19). 
 
Figure 3.19 Asymmetric unit of PGLGAH•2H2O. 
The remaining O-H and the carbonyl moieties of the PGL molecules interact with GAH 
and water molecules respectively (not shown in the figure). The hydrogen bond distances 
observed for these interactions are 2.725 (2) Å and 2.885 (3) Å. The overall hydrogen 
bonding generates 2-D network as presented in Figure 3.20. 
 
Figure 3.20 Overall hydrogen bonding in PGLGAH•2H2O. 
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3.6 Discussion: 
Of all the catechol cocrystals considered for this study, 11 are reported herein and six 
(CFANAM•H2O, GALADN, GALDMP, GALINZ, GALGAH and QUEINM,) have 
been reported elsewhere.
25,26,32
 Out of 17 cocrystals,  15 of them are sustained by 
supramolecular homosynthons (12 are sustained by the catechol dimer and three are 
sustained by amide dimer). The two cocrystals which were not sustained by any 
supramolecular homosynthon are EGLINZ•2H2O and PGLGAH•2H2O. Even though 
CFANAM•H2O and CFAINM•2H2O were also hydrates they exhibit catechol and 
amide dimers respectively. In this context the cocrystals of carbamazepine (CBZ),
29,30,31 
one of the most studied pharmaceutical cocrystals, are more appropriate examples which 
exhibit supramolecular homosynthon (amide dimer) during the cocrystal formation. Of 
all the reported 34 cocrystals of CBZ, 18 cocrystals are sustained by amide dimer (CBZ) 
where the CCFs hydrogen bond to the peripherals of the dimer. Figure 3.21 illustrates the 
CBZ-saccharin (UNEZAO) and CBZ-nicotinamide (UNEZES) cocrystals where the 
cocrystal is sustained by the amide dimer of CBZ whereas the CCF molecules H-bond to 
the dimer on the peripherals. 
 (a)   
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(b)  
Figure 3.21: (a) CBZ-Saccharin cocrystal; (b) CBZ-Nicotinamide cocrystal. 
 
The relative strength of supramolecular homosynthon exhibited by amides is greater 
when compared to carboxylic acids, alcoholic O-H and phenolic O-H functionalities as 
demonstrated by Infantes et al.
32
 According to their report, the relative strength of the 
supramolecular homosynthons is amides > acids > alcohols. Their study revealed that the 
carboxylic acid supramolecular homosynthons can be overcome in the presence of other 
functional groups whereas the amide dimers are relatively strong. But, in the present 
study the cocrystals EGLGAH and MGLGAH were sustained by catechol dimer even in 
the presence of GAH molecule which is capable of forming the amide dimer as in 
CFAGAH and PCAGAH. This could be attributed to the erratic nature of catechols 
which brings in a huge diversity in terms of supramolecular synthons as exemplified by 
the cocrystals reported in here. 
In order to compare the frequency of occurrence of the catechol dimer, the 
hydrogen bonding in the cocrystals have been compared to the individual polyphenols 
including their corresponding hydrates. Among the seven catechols (present study), only 
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MGL exist in the anhydrous form with the crystal structure reported in the CSD (Table 
2.3) whereas, CFA, EGL and PGL exist only as hydrates. GAL and PCA exist in both 
hydrate and anhydrous forms with reported crystal structures. The anhydrous form of 
GAL exhibit supramolecular synthon II and its four (3
rd
 and 4
th
 forms has been reported 
by Clarke et al)
33
 polymorphic monohydrates exhibit supramolecular synthons I, II and 
IV emphasizing the promiscuity of water leading to various hydrogen bonds satisfying 
the donor-acceptor ratios. PCA exhibit the catechol dimer in its anhydrous form whereas, 
its hydrate exhibit supramolecular synthons II and IV. No other polyphenol has been 
found to exhibit supramolecular synthon I in anhydrous or hydrate form.  
Table 3.2 Supramolecular homo and heterosynthons observed in the cocrystals. 
Supramolecular synthon Cocrystals 
Synthon-I  
(O-H∙∙∙O-H) 
CFANAM•H2O, CFAINZ, EGLDMP, EGLGAH, GALADN, 
GALDMP, GALGAH, GALINZ, MGLGAH, MGLINZ, PGLDMP, 
QUEINM  (12) 
Synthon-II - 
Synthon-III 
(O-H∙∙∙water∙∙∙O-H) 
CFANAM•H2O, EGLINZ•2H2O (2) 
Synthon-IV 
(O-H∙∙∙water) 
CFAINM•2H2O,  EHLINZ•2H2O, PGLGAH•2H2O  (3) 
O-H∙∙∙C=O 
CFAINZ, CFAGAH, EGLDMP, EGLGAH,  MGLGAH, MGLINZ, 
PCAGAH, PGLDMP, PGLGAH•2H2O, QUEINM  (10) 
Amide dimer CFAINM•2H2O, CFAGAH, PCAGAH (3) 
Acid dimer - 
Acid-Amide dimer CFANAM•H2O (1) 
COOH∙∙∙Narom CFAINM•2H2O, CFAINZ (2) 
O-H∙∙∙Narom 
EGLDMP, EGLINZ•2H2O, GALADN, MGLINZ, PGLDMP, 
QUEINM (5) 
*The number in the parenthesis represents the total no. of cocrystals exhibiting the synthon.  
 
This observation suggests that the catechol dimer is not very prominent in single 
component systems (catechols alone) whereas in multicomponent systems such as 
cocrystals, the dimer is more frequently observed. Therefore, it could be possible that the 
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cocrystallization is capable of yielding the catechol dimer. Of all the cocrystal hydrates 
containing catechol moiety (reported in the present study as well as in the CSD) only one 
cocrystal CFANAM•H2O exhibited the catechol dimer. This observation implies that the 
presence of water molecules more than likely prevents the formation of the catechol 
dimer.   Apart from the supramolecular synthons listed in scheme I, various other 
synthons are also exhibited (Table 3.2) by the cocrystals. The O-H∙∙∙C=O supramolecular 
heterosynthon also occurred equally with catechol dimer indicating the reliability of the 
synthon between hydroxyls and the carbonyl compounds. 
Table 3.3 List of catechols and their corresponding hydrates with CSD ref codes and the 
supramolecular synthon exhibited by them. 
 
Polyphenol CSD ref code 
Supramolecular 
synthon exhibited 
CSD ref code of the 
corresponding 
hydrate(s) 
Supramolecular 
synthon 
exhibited 
CFA 
No structure 
reported 
NA FESNOG
34
 II, IV 
GAL IJUMEG
35
 II 
KONTIQ
36
 IV 
KONTIQ01
37
 I, IV 
Form III
35
 I, IV  
Form IV
35
 
(KONTIQ03)
38
 
II, IV 
MGL ROMGAC
39
 II No hydrates reported NA 
EGL 
No structure 
reported 
NA No hydrates reported NA 
PGL 
No structure 
reported 
NA FACVAH
40
 IV 
PCA WUYNUA
41
 I BIJDON04
43
 II, IV 
QUE 
No structure 
reported 
NA FEFBEX01
42
 III 
 
Amide dimers are also exhibited by cocrystals CFAINM•2H2O, CFAGAH, and 
PCAGAH•2H2O even in the presence of other functional groups such as carboxylic acid 
and Narom functionalities. Of the six cocrystals (CFAINM•2H2O, CFANAM•H2O, 
CFAGAH, CFAINZ, GALADN, GALGAH, GALDMP, GALINZ and PCAGAH) 
that contain a carboxylic acid moieties none of them exhibited the acid dimer. This 
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establishes the fact that supramolecular heterosynthons are more prominent than 
supramolecular homosynthons. The robust COOH∙∙∙Narom and O-H∙∙∙Narom supramolecular 
heterosynthons are also observed in some of the cocrystals.  
3.7 Conclusions:   
Most of the nutraceuticals with catechol moieties are rich in antioxidant properties are 
relevant in the pharmaceutical industries either as dietary supplements or as excipients 
which have been understudied in the context of crystal engineering. Some of the phenolic 
acids used in the present study are suitable candidates as potential CCFs. The present 
study demonstrates that the O-H∙∙∙O-H (catechol dimer) supramolecular homosynthon 
does not resist the formation of cocrystals in catechols. From Table 3.3 it is evident that 
most of the catechols do not have the crystal structure reported in the CSD and thus it is 
difficult to conclude that whether the catechol dimer is persistent in single component 
systems or multi component systems. Nevertheless it is observed in the present study that 
the supramolecular homosynthons and heterosynthons occur almost at the same 
frequency in catechol cocrystals. Even though supramolecular heterosynthons are 
considered to be the key factor in sustaining a cocrystal, supramolecular homosynthons 
are equally dominant in catechols cocrystals. However, the CSD does not contain enough 
data for cocrystals that contain catechols to evaluate the reliability of the catechol dimer 
in catechols cocrystals. It is evident from the absence of adequate data from the CSD that 
this class of compounds is relatively less explored in the context of cocrystals, thus 
offering an opportunity to study and understand the supramolecular chemistry of 
catechols.  
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Table 3.4 Crystallographic data and structure refinement parameters for the cocrystals. 
 
CFAGAH 
CFAINM• 
2H2O 
CFAINZ EGLDMP EGLGAH 
EGLINZ• 
2H2O 
Formula C13H14N2O6 C15H18N2O7 C15H15N3O5 C14H18N2O5 C22H26N2O12 
C39H48N6O1
9 
MW 294.26 338.31 317.30 294.30 510.45 904.83 
Crystal system Triclinic Triclinic Triclinic Triclinic Triclinic Triclinic 
Space group P-1 P-1 P-1 P-1 P-1 P-1 
a (Å) 6.1600 (3) 8.5694(1) 7.4163 (3) 7.4755 (2) 11.7057 (2) 9.3112(2) 
b (Å) 8.0178 (4) 9.4912(2) 9.7537 (3) 9.7262 (3) 12.5290 (3) 14.4155(3) 
c (Å) 13.4643 (6) 9.5505(2) 10.3709 (4) 10.9370 (3) 13.0113 (3) 17.2588(3) 
 (deg) 90.271 (3) 93.312(1) 74.085 (2) 97.051 (2) 115.285 (1) 108.323(1) 
 (deg) 101.790 (3) 91.537(1) 84.020 (2) 94.327 (2) 93.711 (1) 101.024(1) 
 (deg) 96.325 (3) 99.397(1) 78.768 (2) 109.148 (2) 106.499 (1) 99.991(1) 
V /Å3 646.75 (5) 764.56(2) 706.59 (5) 739.83 (4) 1615.85 (6) 2089.60 (7) 
Dc/mg m
-3 1.511 1.470 1.491 1.321 1.574 1.438 
Z 2 2 2 2 3 2 
2 range 3.35 to 65.52 4.64 to 65.97 4.44 to 62.33 4.10 to 65.48 3.85 to 67.44 
2.80 to 
66.57 
Nref./Npara. 2135 /201 2534/350 2183/232 2409/196 5379/500 6920/650 
T /K 225 (2) 100 (2) 100 (2) 293 (2) 100 (2) 100 (2) 
R1 [I>2sigma(I)] 0.0347 0.0365 0.0594 0.0459 0.0419 0.0474 
wR2 0.0900 0.0975 0.1553 0.1241 0.1071 0.1185 
GOF 1.028 1.057 0.962 1.043 0.992 1.030 
Abs coef. 1.035 1.003 1.021 0.848 1.112 0.991 
 MGLGAH MGLINZ PCAGAH PGLDMP 
PGLGAH• 
2H2O 
 
Formula C20 H22 N2O12 C22H23N3O11 C11H12N2O6 C15H20N2O5 C24H34N2O14  
MW 482.40 505.43 268.23 308.33 574.53  
Crystal system Monoclinic Monoclinic Monoclinic Monoclinic Monoclinic  
Space group C2/c P21/c P21/n P21/n P21/c  
a (Å) 26.1861 (7) 10.3058(5) 8.0640 (3) 7.7170 (2) 15.6501(3)  
b (Å) 3.7362 (1) 11.8783(5) 6.4791 (2) 8.8082 (2) 4.80800(10)  
c (Å) 20.7953 (6) 17.7690(6) 22.3446 (6) 23.1797 (4) 17.4557(3)  
 (deg) 90 90 90 90 90  
 (deg) 108.232 (1) 94.857(3) 97.610 (2) 99.042 (1) 100.9240(10)  
 (deg) 90 90 90 90 90  
V /Å3 1932.40 (9) 2167.39 (16) 1157.17 (6) 1556.01 (6) 1289.67 (4)  
Dc/g cm
-3 1.658 1.549 1.540 1.316 1.480  
Z 4 4 4 4 2  
2 range 3.55 to 65.80 4.31 to 63.01 3.99 to 66.45 3.86 to 67.68 5.16 to 67.29  
Nref./Npara. 1609/158 3206 /333 1971/184 2693/211 2251/206  
T /K 100 (2) 100(2) 100 (2) 100 (2) 100(2)  
R1 [I>2sigma(I)] 0.0354 0.0460 0.0392 0.0419 0.0422  
wR2 0.0946 0.1092 0.1064 0.0995 0.1070  
GOF 1.068 1.023 1.099 1.044 1.052  
Abs coef. 1.202 1.081 1.095 0.830 1.027  
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Table 3.5 Selected hydrogen bond distances and parameters for the cocrystals reported herein. 
 
H-Bond 
d (H•••A) 
/Å 
D 
(D∙∙∙A)/Å 
θ /º  H-Bond 
d (H•••A) 
/Å 
D (D∙∙∙A)/Å θ /º 
CFAGAH 
O-H···O 1.89 2.700 (2) 165.2 
PGLGAH•
2H2O 
O-H···O 1.96 (3) 2.780 (2) 165 (3) 
O-H···O 1.97 2.722 (2) 150.8 O-H···O 2.36(3) 2.738 (2) 108 (2) 
O-H···O 1.84 2.651 (1) 167.2 O-H···O 1.84 (4) 2.639 (2) 157 (4) 
N-H···O 2.00  2.917 (2) 177 (2) N-H···O 2.27 (3) 3.112 (3) 153 (3) 
N-H···O 1.99  2.892 (2) 167 (2) N-H···O 2.36 (3) 2.947 (3) 141 (3) 
CFAINM•
2H2O 
O-H···O 1.95 (3) 2.838 (6) 172(2) 
MGLGAH 
O-H···O 1.86 2.688 (2) 170.6 
O-H···O 1.80 (3) 2.687 (1) 175(2) O-H···O 1.94 2.720 (2) 153.5 
O-H···O 2.02 (3) 2.854 (1) 161(2) O-H···O 2.32 2.755 (2) 112.6 
N-H···O 2.08 (3) 2.935 (2) 163.2(2) N-H···O 2.19   3.060 (2) 168.0 
N-H···O 2.01 (2) 2.9201(2) 174.6(2) 
MGLINZ 
O-H···N 1.89 2.661 (3) 152.3 
CFAINZ 
O-H···O 2.07 (4) 2.748(3) 131 (3) O-H···O 2.21 2.915 (3) 141.0 
O-H···O 2.14 (4) 2.739 (3) 123 (3) O-H···O 1.86 2.680 (3) 166.9 
N-H···O 2.32 (3) 3.148 (3) 145 (3) N-H···O 2.16 2.953 (3) 149.2 
N-H···O 2.48 (3) 2.977 (3) 112 (2) N-H···O 2.38 3.118 (3) 142.1 
N-H···O 2.50 (3) 3.329(3) 146 (3) 
PCAGAH 
O-H···O 1.79 2.620 (2) 169.0 
EGLDMP 
O-H···O 2.01 2.654 (2) 135.2 O-H···O 1.89 2.721 (2) 169.0 
O-H···O 2.28 2.714 (2) 113.5 O-H···O 1.91 2.572 (2) 135.0 
O-H···O 1.92 2.705 (2) 158.7 N-H···O 2.05 (2) 2.941 (2) 171 (2) 
O-H···O 1.90 2.720 (2) 177.7 N-H···O 2.05 2.941 (2) 171 (2) 
N-H···O 2.10 2.832 (2) 142.2 N-H···O 2.19 2.947 (2) 147 (2) 
EGLGAH 
N-H···O 2.01 2.950 (2) 165.5 
PGLDMP 
O-H···O 1.85 2.687 (2) 172.1 
N-H···O 2.48 3.108 (2) 122.5 O-H···O 1.97 2.664 (2) 138.9 
O-H···O 1.91 2.739 (2) 169.0 O-H···O 226 2.710 (2) 113.6 
O-H···O 2.00 2.694 (2) 139.5 O-H···O 1.88 2.689 (2) 161.3 
O-H···O 2.27 2.711 (2) 113.2 N-H···O 2.01 (2) 2.818 (2) 146.9 
EGLINZ• 
2H2O 
O-H···N 1.879 (2) 2.756 (3) 170 (3) 
PCAGAH 
O-H···O 1.89   2.721 (2) 169.0 
O-H···O 1.91 (4) 2.778(2) 171(3) O-H···O 1.91 2.572 (2) 135.0 
O-H···O 1.79 (4) 2.631 (2) 160 (4) O-H···O 1.79 2.620 (2) 169.0 
N-H···O 2.31 (2) 3.191 (3) 166 (3) N-H···O 2.05 (2)  2.941 (2) 171 (2) 
N-H···O 2.38 (2) 3.143 (3) 145 (3) N-H···O 2.60 (2)  3.174 (2) 122 (2) 
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CHAPTER 4 
 
Crystal Engineering of p-Coumaric acid: Synthesis and solubility studies of 
cocrystals 
 
4.1 Introduction 
Nature has an immense reserve of the finest examples of supramolecular architectures 
sustained by molecular self-assemblies which are governed by non-covalent interactions. 
Inspired by these examples crystal engineering emerged as an important tool in 
supramolecular chemistry which aids in the invention of new molecular structures with 
desired properties. Thus, the primary motto of crystal engineering could be stated as 
“making crystals with purpose”. The new molecules are designed through supramolecular 
synthons and yet not limited to robust synthons which gives room for new 
supramolecular synthons to be discovered. Pharmaceutical cocrystals are one of the 
important outcomes of crystal engineering which furnish opportunities for the active 
pharmaceutical ingredients (APIs) to fine-tune their properties. Current literature is 
loaded with plenty of examples where the physico-chemical and pharmacokinetic 
properties such as solubility, dissolution rate, stability and bioavailability have been 
greatly modified via cocrystallization.        
 Nutraceuticals, whose legal position on the legislative grounds is marginal 
between pharmaceutics and food
1
, offer a wide array of molecules which are worth 
studying due to: a) health benefits associated with them; b) limited solubilities and bio-
availabilities; c) availability of amphiprotic functionalities such as O-H suitable for H-
bonding.  The term nutraceutical was coined by Stephen De Felice in 1976.
2
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Nutraceuticals are widely distributed in nature.
3
 They exhibit many biologically 
significant functions, such as protection against oxidative stress, degenerative diseases 
and are best known for their anti-oxidative properties.
4
 Because of these characteristic 
properties of nutraceuticals we focused our research on the crystal engineering of 
nutraceuticals.
5
 As a part of this, our work deals with the crystal engineering of 
hydroxycinnamic acids namely p-coumaric acid (COU), caffeic acid (CFA) and ferulic 
acid (FER) that includes the synthesis, characterization, and the study of their properties. 
The cocrystals of CFA and FER have been reported elsewhere.
6
 The study also focuses 
on how the substituents on the hydroxycinnamic acid have an effect on the crystal 
packing and the aqueous solubilities of the cocrystals. 
COU is a nutraceutical which is one of the most abundant hydroxy derivatives of 
cinnamic acid (Figure 4.1). It is found in a wide variety of edible plants such as peanuts, 
tomatoes, carrots, apples, pears, grapes, beans, spinach leaves and garlic
7
 including 
beverages such as coffee, tea, wine, chocolate, beer and in olive oil.
8
 It is readily 
absorbed from the gastrointestinal tract via the monocarboxylic acid transporter.
9
 COU is 
a nutraceutical
17,10
 which has antioxidant properties that protects against low-density 
lipoprotein (LDL) and is believed to reduce the risk of stomach cancer
11
  by reducing the 
formation of carcinogenic nitrosamines.
12
 A study conducted by Zang et al revealed that 
COU effectively scavenges •OH in a dose-dependent manner.15(c) In various studies 
conducted by different groups, COU helped in reducing the plasma cholesterol levels
15(c)
 
and found to possesses anti-inflammatory properties,
13
 a weak antileukemic activity
14
 and 
goitrogenic activity.
15
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Figure 4.1 Structure of COU. 
The primary focus of the present study is crystal engineering of multicomponent crystals 
of COU and to investigate (a) the effect of cocrystallization on its solubility and (b) the 
correlation of solubility and melting point (MP) between the CCF and the cocrystal. So 
far five cocrystals of COU have been reported in the Cambridge Structural Database 
(CSD) with caffeine (1:1 and 1:2), theophylline (two polymorphic cocrystals, Forms I 
and II) and 2,3,5,6-tetramethylpyrazine.
16,17
 A third polymorph of COU cocrystal with 
THP is reported in the present report. 
4.2 Selection of CCFs for COU based on CSD analysis 
The functional groups that are present in COU are carboxylic acid and hydroxyl 
(phenolic) and understanding the supramolecular chemistry of these functionalities aids 
in the selection of appropriate CCFs. Carboxylic acids can behave as both acceptor and a 
donor which form complementary hydrogen bonds and tend to exist as dimers. The 
statistics obtained from the CSD reveal 30.1% of the total structures (9362 total 
structures) are sustained by acid dimers in the presence of other competing functional 
groups and 76% in the absence of other competing groups. Phenols are less acidic than 
carboxylic acids but more acidic than aliphatic alcohols. The weak acidic nature of 
phenol can be attributed to the stable phenoxide ion that is formed after the loss of proton 
due to resonance. From the archived literature and the statistics obtained from the CSD, 
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certain functional groups such as Narom are obvious to form hydrogen bonds with 
carboxylic acids and phenols. In this context, Shattock et al has extensively studied the 
hierarchy of supramolecular synthons between carboxylic acids and hydroxyls with basic 
Narom.
18
 Their study revealed 98% occurrence of the COOH
…
Narom supramolecular 
heterosynthon and 78% occurrence of the OH
…
Narom supramolecular heterosynthon in the 
absence of other competing functionalities. The basic nitrogen has a higher probability of 
breaking the supramolecular homosynthon (acid dimer) among the carboxylic acids and 
form a robust COOH
…
Narom at a greater percentage.  Figure 4.2 represents the most 
probable interactions among acids, amides, phenols and Narom functionalities. 
OH
O NH
O
H
OH
O
N
OH N
I II
III  
Figure 4.2 (i) Acid-amide supramolecular heterosynthon; (ii) COOH
…
Narom supramolecular 
heterosynthon; (iii) OH
…
Narom supramolecular heterosynthon. 
 
Similar searches for the occurrence of supramolecular heterosynthon for carboxylic acids 
and phenols with other functionalities such as carbonyls, purines and amides were 
conducted in the absence of other competing functionalities. The results from the 
searches revealed that amides have 82 and 80% of chances of hydrogen bonding with 
phenols and carboxylic acids respectively. Likewise, there is 55% chance of occurrence 
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of hydrogen bonding between carboxylic acids and phenols.   The supramolecular 
heterosynthons of carboxylic acids with functional groups such as carbonyls and phenols 
occur at 39.9 and 33.3% respectively. Thus, CSD is a valuable tool in selection of 
appropriate CCFs for the target molecules based on the statistical analysis. The crystal 
structure of COU (Ref code: COUMAC01) reported in the CSD reveals that the COU molecules 
form acid dimers and O-H···O-H hydrogen bonds.
19
 Therefore, in order to make the cocrystals of 
COU these supramolecular homosynthons have to be overcome. In a supramolecular point of 
view COU has carboxylic acid and phenolic hydroxyl moieties that could act as acceptors and 
donors as well. The evidence from the CSD statistics and the literature reveal that carboxylic acid 
and hydroxyl functional groups exhibit a variety of hydrogen bonding motifs and perceivably to 
some extent one can predict supramolecular heterosynthons that involve these two groups even in 
the presence of other competing functional groups.
18
  
4.3 Experimental Section 
 
To synthesize cocrystals of COU, the CCFs nicotinamide (NAM), isonicotinamide 
(INM), isonicotinic acid (INA), isoniazid (INZ), urea (URE), theophylline (THP), 
theobromine (TBR), betaine (BTN) listed in Figure 4.3 are used 
N
CONH
2
N
CONH
2
N
COOH
N
NHNH
2
NH
N N
O
O
N
+
O
O
O
NH
2
NH
2
NAM INA INZ
TBR BTN
UREINM
N
N
N
H
N
O
O
THP
 
 
Figure 4.3 Structures of cocrystal formers with the three letter code. 
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. All reagents were obtained from commercial suppliers and used without further 
purification.  All solvents were distilled prior to their use. 
 
4.3.1 Preparation of cocrystals via solvent-drop grinding
20
: Stoichiometric amounts 
of starting materials were ground for five minutes in the presence of solvents such as 
methanol, DMF, water (10 μL of per 50 mg of starting material) or in the absence of 
solvent (neat grinding) using an agate mortar and pestle. The resulting powders were 
characterized by powder X-ray diffraction (PXRD), differential scanning calorimetry 
(DSC) and Fourier transform infra-red spectroscopy (FT-IR).  
4.3.2 Preparation of cocrystals via slurrying: Stoichiometric amounts of starting 
materials were slurried overnight (1 mL of water, per 500 mg of starting material). The 
undissolved solid is isolated by filtration and characterized using PXRD, DSC and FT-IR. 
4.3.4 Preparation of single crystals: Single crystals for the cocrystals are obtained by 
dissolving the starting materials in appropriate solvent(s) followed by slow evaporation. 
All reagents were obtained from commercial suppliers and used as such without further 
purification. Specific details are as follows: 
Coumaric acid • Nicotinamide, COUNAM: COU, 228.1mg (1.380 mmol) and NAM, 
170.2 mg (1.390 mmol) were mixed in 2 mL of ethanol and slurried overnight. The 
resulting solution was filtered by using a filter paper. The resulting filtrate was left for 
slow evaporation in the hood and the precipitate was analyzed by powder x-ray 
diffraction. Colorless crystals of COUNAM were harvested after three days (MP = 
159°C).  
Coumaric acid • Isonicotinamide, COUINM-I (1:1): COU, 228.1mg (1.380 mmol) and 
INM, 170.2 mg (1.390 mmol) were mixed in 2 mL of ethanol and slurried overnight. The 
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resulting solution was filtered by using a filter paper. The resulting filtrate was left for 
slow evaporation in the hood and the precipitate was analyzed by powder x-ray 
diffraction. Colorless crystals of COUINM-I were harvested after two days (MP = 
172°C). 
Coumaric acid • Isonicotinamide, COUINM-II (1:2): COU, 16.7 mg (0.100 mmol) and 
INM, 30.0 mg (0.500 mmol) were dissolved in 3 mL of ethyl acetate by heating on a 
hotplate. The resulting solution was left for slow evaporation in the hood Colorless 
crystals of COUINM-II were harvested after four days (MP = 165.5°C). 
Coumaric acid • Theophylline, COUTHP : COU, 16.4 mg (0.100 mmol) and THP 
anhydrous, 18.0 mg (0.100 mmol) were mixed in 3 mL of ethanol and the resulting 
solution was left for slow evaporation in the hood. After two days colorless needles of 
COUTHP were obtained (melting point = 223.4°C).  
Coumaric acid • Theobromine dihydrate, COUTHB•2H2O: COU, 16.4 mg, (0.100 
mmol) and TBR, 17.0 mg (0.100 mmol) were mixed in 3 mL of 1:1 ethanol/water 
mixture. The resulting solution was left for slow evaporation in the hood. Colorless 
crystals of COUTBR•2H2O were harvested after five days (MP = 228.04°C).  
Coumaric acid • Theobromine, COUTBR: COU, 16.4 mg, (0.100 mmol) and TBR, 
17.0 mg (0.100 mmol) were mixed in 3 mL of 1:1 ethanol/water mixture. The resulting 
solution was left for slow evaporation in the hood. Colorless crystals of COUTBR•2H2O 
were harvested after five days which transform to COUTBR (anhydrate form) with in 
less than 24 h (MP = 228.04°C).  
Coumaric acid • Isoniazid, COUINZ: COU, 16.41 mg (0.1000 mmol) and INZ, 13.71 
mg (0.1000 mmol) were dissolved in 3 mL of ethanol by heating on a hotplate. The 
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resulting solution was placed in the hood for slow evaporation. Yellow plate like crystals 
of COUINZ were harvested the next day (MP = 178°C). 
Coumaric acid • Urea, COUURE: COU, 16.41 mg (0.1000mmol) was dissolved to a 
saturated solution of URE, (≥ 98% pure used as received from Sigma Aldrich) in ethanol. 
The resulting solution was heated on a hotplate and was left at room temperature for slow 
evaporation. Colorless needles of COUURE were harvested after six days (MP 
=123.5
o
C). 
Coumaric acid • Betaine, COUBTN: COU, 1.641 g (0.010mol) and BTN, 4.684 g 
(0.020mol) were added to 3 mL of water and slurried for two days. The resultant mixture 
was left for slow evaporation. Colorless crystals of COUBTN are obtained after a week.  
(MP =170.9 
o
C). 
Coumaric acid • Iso-nicotinic acid, COUINA: COU, 1.641 g (0.010mol) and INA, 1.23 
g (0.010mol) were added to 3mL of water and slurried overnight. The resultant yellow 
colored powder was left for drying and is analyzed by PXRD, DSC and TGA to confirm 
the formation of cocrystal. The crystal structure of COUINA is obtained from the PXRD 
pattern. (MP =217.8 
o
C). 
4.4 Characterization of Cocrystals 
4.4.1 Differential scanning calorimetry (DSC): Thermal analysis was performed on a 
TA Instruments DSC 2920 Differential Scanning Calorimeter. Aluminum pans were used 
for all samples and the instrument was calibrated using an indium standard. For 
reference, an empty pan sealed in the same way as the sample was used.  Using inert 
nitrogen conditions, the samples were heated in the DSC cell from 30°C to the melting 
point of the cocrystal at a rate of 10°C/min. Table 2 lists the melting points of the all the 
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cocrystals obtained by DSC and the melting points of the starting materials obtained from 
the literature.  
4.4.2 Thermogravimetric analysis (TGA): A Perkin Elmer STA 6000 Simultaneous 
Thermal Analyzer was used to conduct thermogravimetric analysis. Open alumina 
crucibles were used to heat the samples from 30°C to the required temperature at 10 
°C/min scanning rate under nitrogen stream. 
4.4.3 Infrared spectroscopy (FT-IR): Characterization of the cocrystals by infrared 
spectroscopy was accomplished with a Nicolet Avatar 320 FT-IR instrument. Sample 
amounts of 1-2 mg were used and spectra were measured over the range of 4000 – 
400cm
-1
 and analyzed using EZ Omnic software. 
4.4.4 Ultraviolet/Visible Spectroscopy (UV/Vis): UV/vis analysis was performed on a 
Perkin-Elmer Lambda 900 UV/vis/NIR spectrometer for dissolution studies. 
4.4.5 Powder X-ray diffraction (PXRD): A Bruker AXS D8 X-ray powder 
diffractometer was used for all PXRD measurements with experimental parameters as 
follows: Cu Kα radiation (λ = 1.54056 Ǻ); 40 kV and 30 mA; Detector type: Scintillation 
type; Scanning interval: 3-40° 2θ; time per step: 0.5 sec. The experimental and calculated 
PXRD patterns from single crystal structures were compared to confirm the composition 
of bulk materials. 
4.4.6 Single-Crystal X-ray Data Collection and Structure Determination: Crystals 
suitable for X-ray crystallography were selected using an optical microscope. Data for the 
cocrystals were collected on Bruker-AXS SMART APEXII CCD diffractometer with 
monochromatized Cu Kα radiation (λ = 1.54178 Å) connected to a KRYO-FLEX low 
temperature device. Indexing was performed using SMART V5.625 
21(a)
 or using APEX 
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2008 V1-0.
21(b)
 Frames were integrated with Saint Plus 7.51
21(c)
 software package. 
Absorption correction was performed by multi-scan method implemented in 
SADABS.
21(d) 
The structures were solved using SHELXS-97 and refined using SHELXL-
97 contained in SHELXTL V6.10
21(e) 
and WinGX V1.70.01
21(f,g,h)
 programs packages. 
All non-hydrogen atoms were refined anisotropically.  
Table 4.1 Crystallographic data and structure refinement parameters for the cocrystals 
 COUNAM COUINM-I COUINM-II COUTBR COUTBR•2H2O 
Formula C15 H14N2O4 C15 H14N2O4 C21 H20 N4 O5 C16 H16 N4 O5 C16H20N4O7 
MW 286.28 286.28 408.41 344.33 380.36 
Crystal system Monoclinic Triclinic Monoclinic Triclinic Monoclinic 
Space group P21/c P-1 P21 P-1 P21/c 
a (Å) 15.5635 (5) 6.9663 (3) 3.9360 (4) 8.8549 (2) 15.3236 (4) 
b (Å) 6.3162 (2) 7.3890 (5) 10.3970 (8) 9.0831 (2) 8.8959 (2) 
c (Å) 14.1472 (5) 14.6499 (7) 23.6212 (2) 11.2492 (3) 12.9598 (4) 
 (deg) 90 91.135 (4) 90 79.674 (2) 90 
 (deg) 106.043 (2) 99.602 (3) 93.486 (7) 69.785 (2) 102.781 (2) 
 (deg) 90 118.103 (3) 90 67.328 (2) 90 
V /Å3 1336.54 (8) 651.65 ( 6) 964.85(14) 782.32 (3) 1722.87 (8) 
Dc/mg m
-3 1.423 1.459 1.406 1.462 1.466 
Z 4 2 2 2 4 
2 range 5.92 to 67.80 3.08 to 66.77 1.87 to 67.05 4.19 to 67.21 2.96 to 67.38 
Nref./Npara. 2366/214 2165/197 3126/275 2615/275 3033/313 
T /K 100 (2) 100 (2) 293 (2) 293 (2) 100 (2) 
R1 [I>2sigma(I)] 0.0361 0.0408 0.0443 0.0423 0.0362 
wR2 0.0903 0.1034 0.1109 0.1070 0.0911 
GOF 1.040 1.017 1.037 1.014 1.024 
Abs coef. 0.874 0.896 0.853 0.936 0.992 
 
 COUINZ COUURE COUBTN COUTHP-III  
Formula C20H20N4O5.33 C20H20N4O5.33 C14 H15 N3 O3 C16H16N4O5  
MW 401.73 224 273.29 344.33  
Crystal system Monoclinic Monoclinic Triclinic Triclinic  
Space group P21/n C2/c P-1 P-1  
a (Å) 7.3854 (2) 16.0219 (3) 6.4229 (5) 6.8266 (6)  
b (Å) 5.7039 (1) 6.11800 (10) 8.9868 (8) 8.7088 (8)  
c (Å) 32.6563 (6) 19.9780 (3) 12.6875 (11) 26.843 (2)  
 (deg) 90 90 100.371 (4) 90.138 (7)  
 (deg) 92.776 (1) 110.9110 (10) 92.031(5) 92.366 (7)  
 (deg) 90 90 99.829 (5) 99.901 (8)  
V /Å3 1374.05 (5) 1829.3 708.14 (10) 1570.7 (2)  
Dc/g cm
-3 1.456 1.410 1.282 1.456  
Z 4 4 2 4  
2 range 5.42 to 68.37 4.74 to 67.38 3.55 to 66.10 3.30 to 65.08  
Nref./Npara. 2359/260 1592/142 2362/193 5052/463  
T /K 100 (2) 100 (2) 293 (2) 225 (2)  
R1 [I>2sigma(I)] 0.0343 0.0326 0.0548 0.0690  
wR2 0.0978 0.0814 0.1287 0.1593  
GOF 1.011 0.978 1.000 1.009  
Abs coef. 0.900 0.917 0.762 0.932  
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Hydrogen atoms were placed in geometrically calculated positions or found in the Fourier 
difference map and included in the refinement process using riding model or without 
constraints. The crystallographic data for the cocrystals reported herein are presented in 
Table 4.1. 
4.4.7 Crystal Structure Solution from Powder X-ray Diffraction: The cocrystals 
which are crystalline and yet difficult to obtain the single crystals, under such 
circumstances the crystal structure can be solved from the powder X-ray diffraction data. 
In case of COUINA and COUBTN, the crystal structures were solved using 
computational software TOPAS Academic.
22,23
 PXRD measurements are performed at 
beam line X16C of the National Synchrotron Light Source at Brookhaven National 
Laboratory. The samples are lightly ground and loaded into a nominal 1.5-mm diameter 
glass capillary, which is then flame sealed.  X-rays of a particular wavelength are selected 
by a Si (111) channel cut monochromator.  Diffracted X-rays are selected by a Ge (111) 
analyzer and detected by a scintillation counter.  The incident intensity is monitored by 
an ion chamber and used to normalize the measured signal. Structure solution is 
performed by simulated annealing as implemented in TOPAS Academic.  
Table 4.2 Crystallographic data and structure refinement parameters for COUINA 
COUINA (Data obtained from PXRD data using TOPAS Academic software) 
Formula C15H13O5N  (deg) 66.9010 (20) 
MW 287.26 V /Å3 665.610 (37) 
Crystal system Triclinic Dc/g cm
-3 1.43 
Space group P-1 Z 2 
a (Å) 7.41858 (22) 2 range 3.0 to 35.0 
b (Å) 8.93427 (27) T /K 300 
c (Å) 11.36671 (34) Rwp 4.28 
 (deg) 86.9643 (26) R exp 2.06 
 (deg) 74.2132 (22) GOF 2.08 
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From this initial solution, the structure is successfully refined with TOPAS Academic. 
Table 4.2 represents the crystallographic data obtained from PXRD data using TOPAS 
Academic software. 
4.5 Synthesis of Cocrystals in Bulk for Dissolution 
In order to scale up the synthesis of cocrystals from milligram scale to gram can be 
achieved by slurry method. All of COU acid cocrystals were reproduced by slurrying in 
water except COUINM-II (slurried in ethyl acetate) and COUTBR (slurried in ethanol). 
For each cocrystal stoichiometric amounts of the starting materials (except COUBTN 
and COUURE 1:2 ratio were used) in 5-6 mL of solvent are added and stirred overnight 
with the help of a magnetic stir bar on a stir plate. Slurrying resulted in 100% conversion 
of the starting materials to cocrystal. The purity of the bulk material is tested by PXRD 
and DSC. For PXRD the pattern of the bulk material is compared to the PXRD obtained 
from the single crystal X-ray diffraction, and the presence of any additional peaks other 
than the peaks in the calculated pattern indicates starting materials or impurities.  
4.6 Cocrystal Solubility Evaluation: Solubility studies were performed on pure 
COU and its cocrystals including the 1:2 cocrystal of COU with caffeine (COUCAF)
16
 
using UV/vis/NIR spectrophotometry in water. The wavelength used for COU was 
selected as 315 nm where the interference of the CCF is not observed in the UV 
spectrum. A uniform particle size (between 53 and 75 μm) for the bulk powder was 
obtained for all the cocrystals and pure COU by sieving. The dissolution studies are 
conducted by taking approximately 4 grams of the cocrystal in 70 mL of water and were 
stirred with a magnetic stir bar at ca. 125 rpm for 24 hours. Aliquots are drawn from the 
slurry at regular time intervals (5, 10, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 240 
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and 1440 minutes) and filtered using a 0.45 μm nylon filter. The filtrates are diluted 
appropriately and analyzed to measure the concentration of COU (at 315 nm) by using 
UV/VIS/NIR spectrometer.  The remaining solid was analyzed by PXRD and DSC to 
confirm the crystal form. The solubility measurements were done in replicates of three.  
4.7 Crystal Structure Descriptions 
Based on the statistics obtained from CSD for the reliability of supramolecular 
heterosynthon involving phenols and carboxylic acid suitable cocrystals formers were 
targeted. Herein we report structurally characterized ten cocrystals of COU. 
4.7.1 COUNAM: Anticipating the O-H···Narom /acid···Narom supramolecular 
heterosynthons between COU and NAM the cocrystallization experiment was carried on. 
The anticipation was based on supramolecular studies established through various 
studies.
18 
A 1:1 complex was yielded between COU and NAM with four molecules of 
each in the unit cell. The crystal structure reveals that p-coumaric acid and nicotinamide 
molecules exist as acid-amide dimers (N-H···O: 2.911 (2), O-H···O: 2.541 (2) Å) and 
these dimers are connected to other dimers through O-H
…
Narom (2.705 (2) Å) 
supramolecular hydrogen bonds resulting in the formation of a corrugated tape. In the 
crystals structure of COUNAM the acid···amide dimers form a cyclic   
 (8) and a chain 
C(4) graph sets
24
 as illustrated in Figure 4.4. The corrugated tapes are linked through 
C(4) chains which are formed by the lateral hydrogen bonding between the acid and the 
amide moieties (N-H···O-H: 2.947 (2) Å). The overall hydrogen bonding results in the 
formation of a network that could be described as a supramolecular corrugated sheet. 
Nine cocrystals of NAM are reported with molecules containing a COOH and O-H 
moieties in the CSD. Of the nine cocrystals, five are found to be sustained by 
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acid···amide supramolecular heterosynthon and the O-H hydrogen bonds to Narom similar 
to that in COUNAM only when water molecule is not present (three cocrystals). In the 
hydrate cocrystals of NAM with molecules containing a COOH and O-H moieties the 
water molecule interrupts the bond between O-H and Narom. The cocrystals which are 
sustained by amide dimer, the acid moiety hydrogen bonds to Narom and the O-H to anti-
hydrogens of the amide functionality.  
 
Figure 4.4 Intermolecular hydrogen bonding in 1:1 COUNAM cocrystal. 
4.7.2 COUINM I: Slurrying COU and INM in the presence of ethanol results in the 
formation of 1:1 cocrystal, COUINM-I. The cocrystal crystallizes in centrosymmetric 
space group, P-1. The cocrystal is also sustained by the complementary acid-amide 
dimers (N-H···O: 3.040 (2), O-H···O: 2.586 (2) Å) and these dimers are connected to 
other through OH···Narom (2.694 (2) Å) supramolecular hydrogen bonds similar to that in 
COUNAM (Figure 4.5). The only difference lies in the lateral hydrogen bonding that 
occurs between the tapes in both cocrystals. Unlike COUNAM, the tapes are linear and 
form a 2+2 tetramer described by   
 (8) graph set generating a layer. 
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Figure 4.5 Hydrogen bonding in COUINM illustrating the 2+2 tetramer. 
The anti-hydrogens of INM molecules hydrogen bond to the carbonyl of acid moieties 
(N-H···O: 2.981 (2) Å) of the adjacent tapes resulting in the formation of   
 (8) graph set 
as illustrated in Figure 4.5. The layers generated by the 2+2 tetramers align themselves in 
the form of ABCABC as shown in Figures 4.6 (a) and (b) which interacts through weak 
C=O···C-H interactions. 
 
(a)    
 
(b)  
Figure 4.6 Weak interactions between the layers (ABC) generated by the 2+2 tetramers in COUINM-
I (a); side view (b). 
 
 
According to the CSD statistics there are seven cocrystals of INM with CCF containing 
COOH and O-H moieties. Of the seven cocrystals, one cocrystal BUFQAU
25,30 (a) 
is a 
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ternary cocrystal where the acid-amide dimer, COOH···Narom and O-H···C=O 
supramolecular heterosynthons are observed. Three cocrystals exhibit the amide dimer 
along with COOH···Narom O-H···N-H supramolecular heterosynthons. Cocrystal 
MUPNER
26
 exhibits similar kind of 2+2 teteramer (as shown in Fig 4.5) seen in 
COUINM-I.  
4.7.3 COUINM II: Slow evaporation of COU and INM in 1:5 stoichiometric ratio in 
ethyl acetate resulted in 1:2 cocrystal of COUINM-II. Unlike COUINM-I, the 
acid
…
amide dimers are broken. In COUINM-II, two INM molecules interact with one 
COU molecule through and the COOH···Narom (2.691 (4) Å) and O-H···Narom (2.691 (4) 
Å) supramolecular synthons.  
 
Figure 4.7 Supramolecular sheet generated in COUINM-II. 
The amide moieties of INM molecules interact with neighboring INM molecules through 
N-H···C=O H-bonds (2.796 (4) Å). Of the two INM molecules that form the 1:2 
cocrystal with COU, one of the C=O moiety of the INM molecules does not participate in 
the H-bonding. The anti-H atoms of INM molecules interacts with C=O of COU 
molecules in the adjacent tapes (2.969 (4) Å). The overall H-bonding results in the 
formation of a supramolecular sheet as illustrated in Figure 4.7. 
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4.7.4 COUTHP: A third polymorphic cocrystal of COU and THP (Form III, MP: 
223.4 
o
C) has been reported here. Forms I (IJIBEJ, MP: 219.64 
o
C) and II (IJIBEJ01, 
MP: 203.62 
o
C) are reported elsewhere.
16
 These forms were produced concomitantly 
whereas during the synthesis of COUTHP, Forms I and III are produced concomitantly. 
This can be confirmed by the DSC (see supplementary data) which exhibits two 
endotherms which corresponds to Form I and III. The crystal structure of COUTHP 
reveals that COU acid and THP molecules are sustained by dimers represented by   
 (9) 
graph set. The dimer is formed between the N-H of imidazole ring, C=O of the 
pyrimidine ring of THP and the acid moiety of COU molecules  
 
Figure 4.8 Represent the H-bonding in all the three polymorphs of COUTHP. Form II and III with 
their cell parameters. 
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. The dimers are linked to other dimers via O-H···N (basic) hydrogen bonds resulting in 
the formation of undulating tape. Similar kind of dimer is also observed in Forms I and II 
(Figure 4.8). Form II forms undulating tapes similar to that in COUTHP (Form III), but 
when closely observed the dihedral angle between the planes containing COU-THP 
dimers in Form III differs by almost 8 degrees from Form II. Figure 4.9 illustrates the 
dihedral angles formed between two COU-THP dimers. When the stoichiometric 
amounts of COU and THP are slurried in water for 24 h, Form III is isolated with no 
traces of Form I found in the endotherm obtained by DSC (see supplementary data), slow 
evaporation produces Form I and III concomitantly.  
 
 
Figure 4.9 Illustration of dihedral angles subtended by the planes containing COU-THP dimers in 
Forms II and III. 
 
 
4.7.5 COUTBR•2H2O & COUTBR: The CSD statistics reveal that carboxylic acids 
are capable of forming cocrystals with xanthines like theobromine, theophylline and 
caffeine which led to the isolation of cocrystal between COU and TBR. The 
cocrystallization between COU and TBR resulted in the formation of dihydrate of 
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COUTBR•2H2O which later transforms to COUTBR eventually. This is example of 
single crystal to single crystal transformation where one crystalline form transforms to 
the other form. In the crystal structure of the cocrystal, COU and TBR molecules are held 
together by an acid-amide dimer (O-H···O: 2.616 (2) Å, N-H···O: 2.847 (2) Å). These 
dimers in turn are connected to other dimers through hydrogen bonding between N-H of 
the imidazole ring of TBR and O-H of COU molecules via two water molecules as 
illustrated in the Figure 4.10 (O-H···N (basic): 2.914 (2) Å, O···O-H: 2.709 (2) Å, O···O-
H: 2.599 (2) Å). The overall hydrogen bonding results in the formation of zigzag tapes. 
The CSD survey for TBR molecule revealed the presence of only two cocrystals 
(CSATBR
27
, MUPPET
25
)
,
 and both of them were synthesized with CCF containing 
COOH and O-H moieties. Both the cocrystals are sustained by the acid-imide dimer 
which is also observed in COUTBR•2H2O. The O-H moiety in CSATBR is involved in 
intramolecular H-bonding with C=O moiety of the acid group whereas in MUPPET the 
O-H and N (basic) interactions are interfered by the insertion of water molecules. 
 
    Figure 4.10 Ball and stick representation single hydrogen bonded tape in the dihydrate of 1:1 
COUTBR.2H2O cocrystal. 
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The weight loss at 102.55 
o
C from the TGA data (see Appendix 18) of COUTBR•2H2O 
corresponds to the loss of single water molecule. It is possible that the water molecules 
are lost gradually once they are out of the mother liquor. This raises the possibility for 
phase transformation of COUTBR•2H2O to a new form. The TGA recorded after 24 h 
on the crystals of COUTBR•2H2O showed no water loss which confirms the complete 
transformation of COUTBR•2H2O to an anhydrous form namely, COUTBR (see 
Appendix 19). So to confirm the identity of the crystals after exposing 
COUTBR•2H2O in air for 24 h, a single crystal was picked and the single X-ray 
diffraction data was collected. The data obtained from the single X-ray diffraction 
confirmed the transformation of COUTBR•2H2O to COUTBR.  
The 1:1 cocrystal of COUTBR is held also held together by the acid-amide dimer 
similar to that in COUTBR•2H2O.  Since the water molecules are not present in 
COUTBR, the O-H moiety of COU interacts with the basic N of the imidazole moiety of 
TBR molecule thereby generating linear tapes as presented in Figure 4.11. 
 
Figure 4.11 Intermolecular interactions in COUTBR. 
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4.7.6 COUINZ: Continuing attempts for crystal engineering of COU with various 
functional groups lead us to target INZ as one of the suitable cocrystal former due to the 
presence of Narom and hydrazine moieties. INZ, drug which is used for the treatment 
against tuberculosis, is an organic compound which contains a hydrazine and Narom 
moieties. The cocrystallization of COU and INZ resulted in 1:1 cocrystal of COUINZ. 
The asymmetric unit of COUINZ cocrystal contains one molecule each of COU and 
INZ. In the crystal structure COU and INZ molecules exist as acid-hydrazine dimers 
described by   
 (7) graph set (O-H···N: 2.601 (2) Å, O···N-H: 2.887 (2) Å). The dimers 
are connected to other adjacent dimers through O-H···Narom (2.736 (2) Å) supramolecular 
heterosynthon.  
 
 
Figure 4.12 Intermolecular hydrogen bonding in the 1:1 COUINZ cocrystal. 
 
 
The hydrogen bonding in COUINZ results in the formation of corrugated tapes as 
illustrated in Figure 4.12. The intermolecular hydrogen bonding between the tapes 
through N-H
…
O hydrogen bond (2.985 (2) Å) result in the formation of C(3) chains as 
shown in Figure 4.13 and therefore, the overall network could be described as a 
supramolecular corrugated sheet. 
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Figure 4.13 Illustration of C(3) chains in COUINZ. 
 
4.7.7 COUURE: COU crystallizes with URE in C2/c space group with 6 formula units 
in the unit cell. The acid dimer is exhibited by COU molecules with a hydrogen bond 
distance of 2.648 (2) Å. The C=O of the acid functionality of COU interacts with the one 
of N-H of each amine moiety of URE through O···N-H hydrogen bond (2.984 (2) Å), 
whereas the remaining N-H of URE hydrogen bonds with the O-H moiety of COU (O-
H···N-H: 2.964 (2) Å). The O-H moiety of COU forms a bifurcated H-bond with the 
C=O moiety of URE through O-H∙∙∙C=O hydrogen bond (2.601 (2) Å). There are four 
cocrystals of URE with molecules that contain both an acid and O-H moiety and out of 
which the acid dimer is observed in only one cocrystal whereas acid-amide dimers were 
observed in two of them. In the remaining one, the O-H moiety of the acid group interacts 
with the N-H of the URE molecule. Overall hydrogen bonding between COU and URE 
leads to the generation of 3-D network as shown in Figure 4.14. 
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Figure 4.14: Illustration of 3-D network in COUURE cocrystal. 
 
4.7.8 COUBTN: The structure for this cocrystal (also COUINA) was earlier 
determined from the PXRD data as we were unable to obtain the single crystals. More 
recently, a slurry of the starting materials in 1:2 stoichiometric ratio in water resulted in 
single crystals of COUBTN from which the structure was determined and compared to 
that obtained from the PXRD data. The results revealed that both structures are in 
agreement with each other. Persistent interactions between carboxylate and acidic O-H 
moieties have already been established in one of our recent publications.
28
 Similar kinds 
of interactions are observed in COUBTN cocrystal. COUBTN crystallizes in P-1 space 
group where the phenolic O-H of the hydroxyl and the carboxylic acid moieties of COU 
interact with carboxylate moiety of BTN molecule (O-H∙∙∙COO- : 2.650 (1), 2.598 (3)). 
This hydrogen bonding results in the formation of a tetramer between two of each COU 
and BTN molecules as illustrated in Figure 4.15.  
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Figure 4.15 Illustration of tetramer formed in COUBTN. 
 
Ten cocrystals of BTN are reported in the CSD, of which five cocrystals are sustained by 
COO
-
···O-H (acidic) interactions. Three cocrystals are sustained by COO
-
···N-H 
supramolecular heterosynthon whereas two cocrystals exhibit COO
-
···COOH 
supramolecular heterosynthon similar to that in COUBTN.  
4.7.9 COUINA: According to the structure solution of COUINA from the PXRD 
powder pattern (TOPAS Academic software) the cocrystal crystallizes in P-1 space 
group. The crystal structure of COUINA reveal that the COU molecules are held by the 
acid dimers (O-H∙∙∙O: 2.643 (2)) and the INA molecules form head-to-tail anti-parallel 
tapes through strong O-H∙∙∙Narom hydrogen bonds (2.493 (2)) as represented in Figure 
4.16. The carbonyl moiety of INA interacts with the O-H of the COU molecules (O-
H∙∙∙C=O: 2.722 (2)). The COU dimers are sandwiched between the linear anti-parallel 
tapes formed by the INA molecules. Overall hydrogen bonding between COU and INA 
results in the formation of a supramolecular sheet. However, there is an ambiguity about 
the existence of INA molecules in neutral form as there is also a possibility of them to 
exist in the zwitterionic form. The existence of the zwitterionic form of INA molecules 
87 
 
has already been exhibited by some of the our nutraceutical cocrystals reported elsewhere 
(CITINA•2H2O, GALINA•H2O, PCAINA•H2O and QUEINA•H2O).
26
  
 
 
Figure 4.16 Supramolecular sheet formed between COU and INA molecules as observed in COUINA. 
 
From the PXRD data it is in fact impossible to locate the position of hydrogen in INA 
molecule but this doesn’t rule out the possibility of INA molecules to exist in the 
zwitterionic form in the cocrystal. Figure 4.17 represents the H-bond distances and the C-
N-C bond angle of INA molecule in the cocrystal and in the pure form.  
 
Figure 4.17 Comparison of H-bond distances and the C-N-C bond angle in pure INA and in the 
cocrystal. 
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The C-O & C=O bond distances of INA the cocrystal and in the pure form are 1.304 Å 
and 1.226 Å & 1.294 Å and 1.215Å respectively whereas the C-N-C bond angles are 
119.99
o
 and 118.91
o
 respectively. In the cocrystal the H-bond between the acid O-H and 
the Narom for INA in the cocrystal (O-H∙∙∙Narom: 2.511Å) is much stronger in the cocrystal 
when compared to bond distance in the pure form of INA (O-H∙∙∙Narom: 2.592 Å). The C-
N-C bond angle and the O-H∙∙∙Narom H-bond distance of INA in the cocrystal are 
consistent with that of observed in the other cocrystals of INA where it exists as 
zwitterion.
26 
The attempts to obtain the single crystals for COUINA were not successful 
so far. 
4.8 Discussion 
COU is weakly acidic with pKa of 4.32 and could form a salt with appropriate base. The 
formation of cocrystals or salts is governed by the rule of thumb according to which a 
cocrystals is produced only when the difference in pKa of two compounds is negative 
(ΔpKa = pKa base- pKaacid < 0 = cocrystal) and a salt in the other case. The pKa and ΔpKa 
values of the CCFs selected for the present study are listed in Table 4.3. The 
cocrystallization experiments with selected CCFs resulted in the isolation of ten 
cocrystals of COU. Even though the ΔpKa of THP and COU is around 4.5, three 
polymorphic cocrystals are formed between the two as opposed to what is anticipated 
(salt) whereas the rest of the cocrystals follow the rule of thumb. The robust 
supramolecular heterosynthon observed in the cocrystals of COU is O-H···Narom 
(COUNAM, COUINM-I, COUINM-II, COUTHB, COUTHP, COUINA and 
COUINZ).  
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Table 4.3 pKa values of COU and the CCFs
29
 
Compound pKa ∆pKa = pKa(CCF) – pKa (COU) 
NAM 0.5, 3.35 -3.82, -0.97 
INM 3.67 -0.62 
INA 1.70, 4.89 -2.8, 0.39 
THP 8.8 4.48 
TBR 0.59,  9.9 -3.73, 5.58 
INZ 1.8, 3.5, 9.5 -2.52, -0.82, 5.18 
URE 0.18 -4.14 
BTN 1.84 -2.48 
 
This demonstrates that the interactions between O-H and Narom follow the hierarchy of 
supramolecular strategy established by a study conducted by Shattock et al.
18  
The 
cocrystals COUNAM, COUINM-I, COUTBR, and COUTBR•2H2O are found to be 
sustained by acid∙∙∙amide dimer overcoming the acid∙∙∙acid and amide∙∙∙amide 
supramolecular homosynthons whereas, the acid dimer in COU remained intact in only 
two cocrystals namely COUINA and COUURE. The CSD statistics reveal that acid-
amide supramolecular heterosynthons occur at 84% that contain only acid and amide 
functional groups. The study of complex formation between acids and amides was of 
interest for a long time. The hydrogen bond range and the mean distance obtained from 
the CSD for the OH···Narom supramolecular heterosynthon are 2.50-3.10 Å and 2.776 (3) 
Å respectively.
18
 It is found that six of the COU cocrystals (COUNAM, COUINM-I, 
COUINM-II, COUTBR, COUINZ) that exhibit this synthon and the hydrogen bond 
distances are lower than the mean value (2.776 (3) Å) indicating strong interactions 
between the O-H and the Narom moieties. The hydrogen bond distances for the two 
cocrystals of COU those are sustained by acid-amide dimer only COUINM-I fall within 
the expected range whereas, COUNAM is found to be lower than the mean value for the 
acid-amide dimer retrieved from the CSD. The hydrogen bond distances observed for 
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various supramolecular synthons sustained by the cocrystals of COU are listed in Table 
4.4.  
Table 4.4 Various supramolecular synthons observed in COU cocrystals with hydrogen bond 
distances as observed in the cocrystals as well as in the CSD. 
 
Supramolecular 
Synthon  
Range  (Å) (CSD) Mean σ (Å) Cocrystal 
Observed 
(Å) 
O-H
…
Narom 2.50 - 3.10  2.776 (3) 
COUNAM 2.705 (2) 
COUINM-I 2.694 (2) 
COUINM-II 2.753 (4) 
COUINZ 2.732 (2) 
COUNAM 
2.541 (2) 
2.911 (2) 
COOH
…
Narom 2.4 – 3.10 2.750 (3) COUINA 2.493 () 
Acid-amide dimer 2.50 - 3.00 2.583 (3) 
COUINM-I 
2.586 (2) 
3.040 (2) 
COUNAM 
2.541 () 
2.911 () 
O-H···C=O 2.42 – 2.85  2.537 (2) 
COUURE 2.601 (2) 
COUINA 2.726 (2) 
O-H
…
COO
- 
& 
COOH
…
COO
-
 
2.40 - 2.80, 
2.42 – 2.86 
2.537 (2) COUBTN 
2.589 (3) 
2.650 (2) 
Acid dimer 2.52 – 2.80 2.662 (3) 
COURE 2.648 (1) 
COUINA 2.632 (2) 
 
The highest solubility for COU in the dissolution profiles of COU cocrystals 
display a wide range of from 0.25 (COUCAF) to 2.08 mg/mL (COUINM-II). The 
solubility of pure COU in water is found to be 0.78 mg/mL. Thus, cocrystallization 
provided a means to modulate the solubility of COU has been exemplified in the context 
of APIs which is well exemplified in the literature where the bioavailability of the API is 
limited due to its low solubility or bioavailability.
30,31,32,33 
Figure 4.18 (a) and (b) 
represents the dissolution profiles of COU and its cocrystals for 24 and 4 hours 
respectively. The highest solubility increase of COU (3.4 fold) is exhibited by 
COUINM-II (1:2 cocrystal) within the first 5 minutes of the dissolution and eventually 
transforms to COUINM-I (1:1 cocrystal) in about 30 minutes.  
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(a)  
 
(b)  
 
(b) 
 
Figure 4.18 Dissolution profiles of COU and its cocrystals: (a) 24 h; (b) 4 h. 
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The conversion of COUINM cocrystal from Form I to II can also be confirmed from the 
PXRD and DSC. The next highest solubilities are exhibited by COUURE and COUBTN 
within 30 minutes of the dissolution by 1.8 and 1.5 fold respectively. Surprisingly, CAF 
and TBR (both forms) reduced the solubility of COU to almost half of its original 
solubility (0.31 and 0.29 mg/mL respectively). The anhydrous form of COUTBR 
displayed a little higher solubility for COU when compared to the hydrate form which 
gradually converts back to the hydrate form within 30 minutes of the dissolution and rest 
of the seven cocrystals increase the solubility of COU. The PXRDs of the left over 
powders obtained after the dissolution reveal that out of ten cocrystals eight of the 
cocrystals are intact up to 24 h and display uniform solubilities. Two cocrystals 
COUBTN and COURE dissociate and fall apart in the solution as evident by the drop in 
the solubility of COU by the end of 24 h of dissolution (Figure 3.18 (a)) which 
approaches to that of COU.  
4.9 Is cocrystal solubility predictable? 
There are a handful of studies which have focused on understanding and predicting the 
solubility of the cocrystal based on its MP and the solubility of the CCF. In a study 
reported by Good and Rodrı´guez-Hornedo to derive a correlation between the solubility 
of the cocrystal and the CCF claimed that with increasing solubility of the CCF the 
solubility of the CC (carbamazepine, caffeine, and theophylline cocrystals) increases.
34
 
Similar kind of correlation was studied between the MP of the CC and the solubility of 
the cocrystal by Newman et al
35
 and found limited dependence which is attributed to the 
multicomponent nature of the cocrystals. Therefore we undertook a similar kind of study 
to investigate if there is a correlation between the solubilities of the CC, CCF and the MP 
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of the CC. To substantiate the dependence of the solubility of the CC on the CCF 
solubility on and the MP of the CC the data obtained from the dissolutions of COU 
cocrystals are utilized.  
Table 4.5 List of COU cocrystals, MP and Smax 
Compound/CC MP (
o
C) Smax (mg/mL) 
COU 225 0.811 
COUNAM 159 1.095 
COUINM-I 172 1.24 
COUINM-II 166 2.082 
COUCAF (1:2) 184 0.305 
COUTHP-III 223 1.29 
COUTBR•2H2O 228 0.289 
COUTBR 228 0.398 
COUINZ 178 1.096 
COUURE 124 1.569 
COUBTN 171 1.386 
 
It is also important to consider the stability of the CC for the following a correlations 
between (a) MP and the solubility of the CC; (b) solubility of the CC and the CCF as the 
solubility of a compound depends on various parameters such as temperature, enthalpy of 
fusion and intermolecular forces acting between the solute and the solvent and the 
particle size of the solute.
36,37
 Since two of the ten COU cocrystals eventually dissociate 
to COU after 24 h dissolution, the concept of Smax used by Bak et al for the correlation 
studies is applied for the present study. Smax represents the highest solubility of the CC 
exhibited during the 24 h dissolution. Table 4.5 enlists the solubilities and MP of COU 
and its cocrystals. Figure 4.19 represents the plot drawn between the MP and Log Smax of 
the CC for COU cocrystals. From the plot it is clear that there is low correlation between 
the two parameters indicating that it is hard to predict the solubility fromm its MP. 
94 
 
 
Figure 4.19 Correlation between the MP and Log Smax of the CC. 
 
However, the cocrystals (COUURE, COUBTN, COUINM-I & II and COUNAM) 
which have low MP exhibited higher solubilities and vice versa (COUTBR•2H2O, 
COUTBR) but these observations are not enough to generalize the correlation between 
the MP and Log Smax of the CC. Similarly, there is 50% variability observed in the 
relative solubility (log values) of cocrystal and CCF with respect to COU. The 1
st
 
quadrant in the plot (Figure 4.20) the points represent the cocrystal (COUNAM, 
COUINM-I & II, COUINZ, COUTHP, COUURE and COUBTN) which have shown 
an increase in the solubility of COU significantly. The points in the 3
rd
 quadrant represent 
the cocrystals (COUTBR•2H2O, COUTBR) where the CCF has lower solubility than 
COU and the cocrystal also decreased the solubility of COU in the cocrystal.  
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Figure 4.20 Correlation between the relative solubility of CCF (Log values) and the cocrystal. 
 
While 4
th
 quadrant represent the cocrystal (COUCAF) which has drastically decreased 
the solubility of COU even though the CCF has higher solubility than COU. From our set 
of cocrystals and their correlations studies, we have found that it is difficult to predict the 
solubility of the cocrystal based on its MP and the CCF. 
4.10 Conclusion: 
We have successfully demonstrated the utilization of crystal engineering in the design 
and synthesis of COU cocrystals with various CCF with varying solubilities. The 
experiments resulted in ten novel cocrystals of COU, including a third cocrystal 
polymorph with THP. The crystal structure for COUINA and COUBTN were 
successfully determined from PXRD patterns. The structures obtained from both the 
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techniques were found to be consistent with each other. Most of the cocrystals of COU 
exhibit strong either COOH···Narom or O-H···Narom supramolecular heterosynthon. The 
results exhibited by COU collectively delineate that this nutraceutical holds a potential to 
be used as an efficient CCF because of its capability of forming cocrystals with a variety 
of functionalities. Thus it can be used as a potential CCF for APIs.  
The dissolution studies of COU and its cocrystals in water display a wide range of 
solubilities for COU. The highest solubility was exhibited by COUINM-II followed by 
COUURE, COUBTN, COUINM-I and COUINZ. All the cocrystals except COUURE 
and COUBTN were found to be stable up to 24 h dissolution. The correlation studies of 
COU cocrystals suggest that it is hard to generalize that using a more soluble CCF will 
always generate a cocrystal with high solubility for the target molecule or vice versa. One 
possibility to account for this variation can be attributed to an insufficient number of 
cocrystals with solubility data when compared to the cocrystals reported in the literature. 
Therefore, we undertook a study to investigate the correlation studies for all the 
cocrystals reported with the solubility data in the literature (unpublished work) and this 
report is a part of that study. It is clear from the present data and the existing evidence 
from the literature that cocrystallization does indeed have the potential to tailor the 
solubility of a compound and could be applied in the field of drug development.  
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CHAPTER 5 
Multi-Component Crystalline Forms of Hydrochlorothiazide (BCS Class IV drug)  
5.1 Introduction 
Most of the drugs (nearly 80%) are solids at room temperature and administrated as oral 
dosage forms. Solubility and bioavailability are two important parameters of solid state 
forms of drug in product development. For every drug the dosage strength is very critical 
to attain the required therapeutic concentration and it becomes more critical when the 
drug has limited solubility. According to biopharmaceutics classification system (BCS)
1
 
the majority of the drugs which have limited bioavailability due to either low solubility 
and permeability fall in to the category of class II and class IV. Solubility of a drug can 
be altered either by covalent or noncovalent modifications. The covalent modification
2
 
approaches involve change of the API into a new species whereas in non-covalent 
modifications the APIs chemical entity is undiminished. Some of the non-covalent 
approaches include the use of excipients (β-cyclodextrins inclusion compounds),3,4 solid 
dispersions,
5
 reduction of particle size (to increase the surface area),
 6
 amorphous forms,
7
 
micellar/surfactant systems
8
 and lipids
9
 to overcome drug limitations such as solubility, 
bioavailability and stability.
10,11
 In the context of solid crystalline forms screening of new 
forms such as polymorphs, solvates (pseudo polymorphs) salts and cocrystals provides 
the means for improving the solubility and bioavailability of an API. However, salt 
formation is confined to ionizable API whereas screening for polymorphs is the matter of 
time and money
12
 spent on the API. Ubiquitously, solvates and hydrates exhibit low 
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solubility
13,14
 when compared to the pure API but of course with some exceptions
15
 
where the solubility is higher. Thus in this situation pharmaceutical cocrystals appear to 
be one of the available option. A pharmaceutical cocrystals can be defined “as multiple 
component crystals in which at least one component is molecular and a solid at room 
temperature (the cocrystal former) and forms a supramolecular synthon with a molecular 
or ionic API
16” 
Pharmaceutical cocrystals represent an alternative approach which allows 
tailoring the physico-chemical properties of APIs. These pharmaceutical cocrystals can 
be designed rationally utilizing the basic concepts of crystals engineering via the 
supramolecular synthon approach.  Many scientists within industry and academia have 
been fascinated by the results demonstrated by pharmaceutical cocrystals for many 
reasons: a) they allow for the modification of non-ionizable APIs, b) they are amenable to 
design, c) the presence of various cocrystal formers (CCFs) approved by the FDA as 
generally recognized as safe (GRAS) provide an opportunity to select preferred cocrystal 
former to achieve tailored property, d) they can be prepared by various methods with 
limited or no use of solvents including grinding. The proliferation of this field has been 
exemplified by many examples in the literature including several patents  
In this context we have targeted hydrochlorothiazide (HCT), a diuretic drug 
belonging to the BCS class IV to synthesize pharmaceutical cocrystals and to study how 
these cocrystals affect the aqueous solubility in comparison to pure API.  HCT suffers 
low solubility and low permeability. The low bioavailability of HCT is attributed to its 
poor aqueous solubility. Attempts have been made by several groups in order to improve 
the solubility of HCT using various techniques. In a study conducted by Padmapriya et 
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al, Captopril is used as a water soluble carrier and by varying the concentrations of the 
carrier the solubility of HCT was enhanced from 0.246 mg/mL to 0.6125 mg/mL when 
compared to the pure form.
17
 Inclusion compounds of HCT with β-cyclodextrin have also 
been synthesized to overcome the solubility limitation. The intrinsic dissolution of the 
inclusion compounds in simulated gastric fluid exhibited an increase in the solubility. In 
this contribution we report pharmaceutical cocrystals of HCT designed through crystal 
engineering studies with the aid of the Cambridge Structural Database (CSD).  
A thorough CSD search revealed the presence of two polymorphic forms of HCT 
(Ref code: HCSBTZ, HCSBTZ01) and nine solvated forms. Nevertheless, four 
polymorphic forms of HCT were reported in a study conducted by Kim et al
18
 on the 
polymorphic nature of HCT and they were characterized by powder X-ray diffraction 
(PXRD) and differential scanning calorimetry (DSC).  
               
   (i)          (ii) 
Figure 5.1 Two polymorphic forms of HCT: HCSBTZ (left) and HCSBTZ01 (right) 
Figure 5.1 represents the two polymorphs of HCT reported in the CSD. In Form-I four 
HCT molecules form a tetramer whereas, in Form-II the 2
o
 sulfonamide engages in the 
formation of a dimer. No cocrystals of HCT are reported in the CSD however, three 
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cocrystals of HCT with nicotinic acid, 18-crown-6 and piperazine have been in a patented 
by Almarson and Zaworotko et al. HCT has multiple acceptors and donors which makes 
it a potential candidate for crystal engineering studies. The CSD contains a handful of 
examples on the cocrystallization of sulfonamide drugs of which most of them are amino 
substituted benzenesulfonamide APIs. Caira et al has done an extensive study on the 
cocrystallization of sulfa drugs, which included sulfadimidine as a model cocrystal 
former with several carboxylic acids.
19
 Piroxicam, (BCS Class II sulfonamide drug) was 
studied by Childs et al
20
 for cocrystallization using carboxylic acids as CCFs. Celecoxib 
(4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzene-sulfonamide) is 
another low soluble API which was targeted for cocrystallization by Hickey et al.
21
 They 
reported one cocrystal of celecoxib with nicotinamide (VIGDAR) which exhibit 
enhanced solubility when compared to the pure drug.         
 
5.2 Selection of CCFs for HCT based on supramolecular synthon approach via  
           CSD analysis  
 
For simplicity the CSD search for HCT was carried out in two fragments. The first 
fragment contains the sulfonamide (both 1
o
 and 2
o
) moiety and the second contains the 2
o
 
amine (Figure 5.2). Chloride being a weak acceptor was not included in the search.  
 
 
 
                               HCT                                               (A)                            (B) 
Figure 5.2 Moieties used during CSD searches for HCT. 
Searches were conducted individually for each fragment with different functional groups 
including carboxylic acids, phenols, basic nitrogen, amides and carboxylates. Table 5.1 
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represents various possible interactions of fragments I and II with different functionalities 
and Table 5.2 enlists the CSD statistics obtained from these searches.  
The CSD statistics reveal that certain functionalities such as amides (71%), Narom 
(65%) and carboxylates (50%) hydrogen bond to various moieties of HCT at higher 
percentages while the other supramolecular synthons occur at lower percentages. 
Therefore, appropriate CCFs such as amides, basic nitrogen compounds and carboxylates 
would be best suitable for cocrystallization experiments for HCT. Functional groups such 
as amides, phenols and carboxylates are well studied in the context of supramolecular 
synthons. Zaworotko et al. have studied the underexplored carboxylates moieties with 2-
aminopyridinium
22
 and weakly acidic hydroxyl moieties
23
.  
Table 5.1 Possible supramolecular heterosynthons for HCT with other functionalities 
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It was found that 2-aminopyridinium-carboxylate supramolecular heterosynthon 
occurs at 97% and weakly acid hydroxyl-carboxylate supramolecular heterosynthon 
occurs at 56%. This shows that carboxylate moieties are still to be explored with other 
functionalities to a greater extent. Thus, using CCFs with carboxylates moieties for HCT 
offers a means to explore them with sulfonamide functionalities. The cocrystal of HCT 
with isonicotinamide (INM) is published elsewhere but is included in here for dissolution 
studies. 
 
Table 5.2 CSD statistics of possible supramolecular synthons in HCT with different functionalities. 
 
 Total hits 
Hits that form supramolecular 
heterosynthon with % of occurrence 
Sulfonamide + acid 132 
III=39 (30%), 
 VI =4 (3%), 
 IX=10 (8%) 
Sulfonamide + amide 17 
II=12 (71%),  
V=12 (71%) 
Sulfonamide + phenols 60 
I=9 (15%),  
IV=16 (27%) 
2
o
 amine + acid 610 
XIII=9 (1%), 
 XIV=137 (22%) 
2
o
 amine + amide 100 XII=26 (26%) 
2
o
 amine + Narom 1070 X=298 (28%) 
2
o
 amine + carboxylate 70 XI=17 (24%) 
Sulfonamide + Narom 104 VII=68 (65%) 
Sulfonamide + carboxylate 2 VIII=1 (50%) 
 
 
5.3 Materials and Methods 
All reagents were obtained from commercial suppliers and used without further 
purification.  All solvents were distilled prior to their use. The molecular structures of 
HCT and the CCFs (with their three letter code) are represented in Figure 5.3. 
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Figure 5.3 Molecular structures of HCT and the CCFs. 
 
5.3.1 Preparation of single crystals: Single crystals for the cocrystals are obtained by 
dissolving the starting materials in appropriate solvent(s) followed by slow evaporation. 
All reagents were obtained from commercial suppliers and used as such without further 
purification. Specific details are as follows: 
Hydrochlorothiazide • Nicotinamide, HCTNAM: Hydrochlorothiazide, 15 mg (0.1000 
mmol) and nicotinamide, 61.0 mg (0.5000 mmol) were added to 4 mL of ethyl acetate 
and heated on a hotplate. The resulting solution was filtered using a filter paper and 
placed in the hood for slow evaporation. Colorless crystals of HCTNAM were harvested 
after two days (melting point =177.9°C). 
Hydrochlorothiazide • Nicotinic acid, HCTNAC: Hydrochlorothiazide, 15mg (0.050 
mmol) and nicotinic acid, 12.1 mg (0.100 mmol) were added to 4 mL of 1:1 
methanol/water and heated on a hotplate. The resulting solution was placed in the hood 
for slow evaporation. Colorless crystals of HCTNAC were harvested after four days 
(melting point =267.9oC). 
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Hydrochlorothiazide • Betaine, HCTBTN: Hydrochlorothiazide, 20 mg (0.067 mmol) 
was added to 3 mL saturated solution of betaine in ethanol. The resulting solution was 
heated on a hotplate and was left at room temperature for slow evaporation. Colorless 
needles of HCTBTN were harvested after three days (melting point =220°C). 
Hydrochlorothiazide • Dimethylglycine, HCTDMG: Hydrochlorothiazide, 300 mg 
(1.01 mmol) and dimethyl glycine, 500 mg (4.85mmol) were added to 7 mL of ethanol 
and heated on a hotplate until a clear solution was obtained. The resulting solution was 
placed in the hood for slow evaporation. Colorless crystals of HCTDMG were harvested 
after a week (melting point =206.3°C). 
The synthesis and the structure description of the cocrystal of HCT with isonicotinamide 
(HCTINM•H2O) has been reported elsewhere. 
5.3.2 Preparation of cocrystals via slurry: Stoichiometric amounts of starting 
materials were slurried in ethanol overnight (1 mL of EtOH, per 500 mg of starting 
material). The undissolved solid is isolated by filtration and characterized using PXRD, 
DSC and FT-IR. 
5.3.3 Differential scanning calorimetry (DSC): Thermal analysis was performed on a 
TA Instruments DSC 2920 Differential Scanning Calorimeter. Aluminum pans were used 
for all samples and the instrument was calibrated using an indium standard. For 
reference, an empty pan sealed in the same way as the sample was used.  Using inert 
nitrogen conditions, the samples were heated in the DSC cell from 30°C to the required 
temperature (melting point of the cocrystal) at a rate of 10°C/min. 
5.3.4 Thermogravimetric analysis (TGA): A Perkin Elmer STA 6000 Simultaneous 
Thermal Analyzer was used to conduct thermogravimetric analysis. Open alumina 
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crucible is used to heat the sample from 30°C to the required temperature at 10 °C/min 
scanning rate under nitrogen stream. 
5.3.5  Infrared spectroscopy (FT-IR): To characterize the cocrystals by infrared 
spectroscopy a Nicolet Avatar 320 FT-IR instrument was used. Sample amounts of 1-2 
mg were used and spectra were measured over the range of 4000 – 400cm-1 and analyzed 
using EZ Omnic software. 
5.3.6  Powder X-ray diffraction (PXRD): A Bruker AXS D8 powder diffractometer 
was used for all PXRD measurements with experimental parameters as follows: Cu Kα 
radiation (λ = 1.54056 Ǻ); 40 kV and 30 mA. Scanning interval: 3–40° 2θ; time per step: 
0.5 sec. The experimental PXRD patterns and calculated PXRD patterns from single 
crystal structures were compared to confirm the composition of bulk materials. 
5.3.7    Single-crystal X-ray data collection and structure determinations: Crystals 
suitable for X-ray crystallography were selected using an optical microscope. Data for the 
cocrystals were collected on Bruker-AXS SMART APEXII CCD diffractometer with 
monochromatized Cu Kα radiation (λ = 1.54178 Å) connected to a KRYO-FLEX low 
temperature device. Indexing was performed using SMART V5.625 
24(a)
 or using APEX 
2008 V1-0.
11(b)
 Frames were integrated with Saint Plus 7.51
11(c)
 software package. 
Absorption correction was performed by multi-scan method implemented in 
SADABS.
11(d) 
The structures were solved using SHELXS-97 and refined using SHELXL-
97 contained in SHELXTL V6.10
11(e) 
and WinGX V1.70.01
11(f, g, h)
 programs packages. 
All non-hydrogen atoms were refined anisotropically. Hydrogen atoms were placed in 
geometrically calculated positions or found in the Fourier difference map and included in 
the refinement process using riding model or without constraints. Table 5.3 contains the 
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crystallographic data and structure refinement parameters for the cocrystals isolated in 
the present study. 
Table 5.3 Crystallographic data and structure refinement parameters for the cocrystals. 
 HCTNAM HCTNAC HCTBTN HCTDMG 
Formula C13H14ClN5O5S2 C13H13ClN4O6S2 C12H19ClN4O6S2 C15H26ClN5O8S2 
MW 419.86 420.84 414.88 503.98 
Crystal system Orthorhombic Orthorhombic Monoclinic Triclinic 
Space group P212121 P212121 P21/c P-1 
a (Å) 7.6392 (2) 7.3412 (3) 9.8569 (2) 10.3649 (7) 
b (Å) 13.2595 (4) 12.9934 (6) 21.6404 (5) 10.7143 (8) 
c (Å) 16.1215 (5) 16.1869 (7) 8.0471 (2) 11.5908 (8) 
 (deg) 90 90 90 78.513 (4) 
 (deg) 90 90 91.507 (1) 68.481 (4) 
 (deg) 90 90 90 67.970 (4) 
V /Å3 1632.98 (8) 1544.02 (12) 1715.91 (7) 1107.21 (14) 
Dc/g cm
-3 1.708 1.810 1.606 1.512 
Z 4 4 4 2 
2 range 4.32 to 67.92 4.36 to 67.14 4.49 to 67.26 4.11 to 65.64 
Nref./Npara. 2871 / 245 2629 / 229 2997 / 278 3638 / 301 
T /K 100 (2) 100 (2) 100 (2) 100 (2) 
R1 [I>2sigma(I)] 0.0283 0.0514 0.0366 0.0491 
wR2 0.0682 0.1160 0.0939 0.1300 
GOF 1.051 0.972 1.047 1.007 
Abs coef. 4.836 5.148 4.613 3.765 
 
5.3.8 Cocrystal Solubility Evaluation: Solubility studies were performed on HCT 
cocrystals including HCTINM•H2O using HPLC in aqueous media. A uniform particle 
size (between 53 and 75 μm) for the bulk powder was obtained for all the cocrystals and 
pure HCT by sieving. The dissolution studies are conducted by taking approximately 4 
grams of the cocrystal in 40 mL of water and were stirred with magnetic stir bar at ca. 
125 rmp for 24 hours. An aliquot is drawn from the slurry after 24 hours in order to 
obtain the thermodynamic solubility of HCT in the cocrystal and filtered using a 0.45 μm 
nylon filter. The filtrate are diluted appropriately and analyzed via HPLC to measure the 
concentration of HCT.  The remaining solid is analyzed by PXRD and DSC to confirm 
the identity. The solubility measurements were done triplicates.  
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5.4 Description of Crystal Structures 
5.4.1 HCTNAM: The cocrystal HCTNAM is a 1:1 cocrystal of HCT and NAM as 
revealed by the crystal structure.  The carbonyl moiety of the amide group in NAM 
molecule hydrogen bond with the sulfonamide moiety of HCT molecule (O···N-H: 3.041 
(3) Å) as represented in Figure 5.4. The NAM molecules also involves in hydrogen 
bonding in a head-to-tail fashion with each other, consequently parallel tapes of NAM 
molecules (N-H···Narom: 2.873 (3) Å) are formed. Ultimately, ribbons of HCT-NAM are 
generated that interacts with other ribbons above and below the plane through N-H···O 
(2.901 (3) Å) hydrogen bonds as shown in Figure 5.5 
 
Figure 5.4 Representation of intermolecular hydrogen bonds in HCTNAM 
The HCT molecules in one tape interacts with other HCT molecules in the adjacent tapes 
via N-H···S=O interactions (2.901 (3) Å). The CSD search for sulfonamide cocrystals 
revealed the presence of four cocrystals with NAM, tartaric acid, antipyrine (phenazone) 
and sulfanilamide as cocrystal formers. In the cocrystal of NAM (VIGDAR)
25
 with 
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celecoxib, NAM molecules maintain the amide dimer, whereas the sulfonyl moieties 
hydrogen bond to the anti-hydrogens of the amide groups of NAM molecules. To the 
contrary, in HCTNAM, the amide dimers of NAM molecules are broken and O···N-H 
prevails as the dominant supramolecular heterosynthon. 
 
Figure 5.5: Overall H-bonding in HCTNAM. 
 
5.4.2 HCTNAC: In the 1:1 cocrystal of HCTNAC, the NAC molecules exist as 
zwitterions supported by the C-O bond distances, 1.252 and 1.261 Å, and the C-N-C 
bond angle of 123
o
. Pure NAC exhibits C-O bond distances of 1.25 Å and 1.289 Å and a 
C-N-C bond angle of 117.9
o
.  
 
Figure 5.6 Intermolecular hydrogen bonding in the tape formed in HCTNAC. 
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The NAC molecules exhibit the formation of head-to-tail chains (O···Narom: 2.639 (2) Å) 
as in pure NAC crystal structure. The HCT molecules also form linear tapes adjacent to 
the NAC chains which are H-bonded to each other via charge assisted O···N-H bonds 
(2.943 (2) Å) as illustrated in Figure 5.6.  
 
Figure 5.7: Lateral interactions of HCT molecules on HCTNAC (NAC molecules are removed for 
clarity). 
 
Each tape interacts on either sides through H-bonding between HCT molecules via N-
H···S=O interactions (2.921 (2) Å) as presented in Figure 5.6 and Figure 5.7 represents 
the overall hydrogen bonding in HCTNAC. The H-bonding in HCTNAC resembles to 
that of in HCTNAM. The overall supramolecular hydrogen bonding results in the 
formation of corrugated tapes that are stabilized by π- π stacking as represented in Figure 
5.8. 
 
Figure 5.8: Interconnections of the adjacent tapes via H-bonds in HCTNAC. 
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5.4.3 HCTBTN: The successful cocrystallization resulted in the formation of 
HCTBTN. The crystal structure of HCTBTN reveals that it is a 1:1 cocrystal of HCT 
and BTN where, the BTN molecules are disordered. The carboxylate moiety of BTN is 
involved in multiple hydrogen bonds. It interacts with the 1
o
 sulfonamide and the amine 
functionality of adjacent HCT molecules. The hydrogen bond distances of the 
carboxylate with the 1
o
 sulfonamide were found to be 2.867 (3) Å and 2.974 (2) Å 
whereas the bond distances with amine functionality was 2.892 (2) Å (Figure 5.9).   
 
Figure 5.9 Formation of a linear chain between HCT and BTN molecules in the cocrystal. 
The linear chains formed in HCTBTN interact with each other via H-bonds formed 
between the 1
o
 sulfonamide moiety of HCT with the 1
o
 sulfonamide moiety of another 
HCT molecule via N-H···S=O (2.862 (2) Å) interaction. The carboxylate also interacts 
with the 2
o
 sulfonamide moiety of HCT via O···N-H hydrogen bond (2.827 (2) Å). The 
overall hydrogen bonding results in the formation of parallel corrugated tapes which 
stack one above the other and stabilize by π- π stacking as shown in Figure 5.10.  
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Figure 5.10 Intermolecular hydrogen bonding in the monohydrate of 1:1 HCTBTN cocrystal. 
 
5.4.4 HCTDMG: The cocrystallization between HCT and DMG resulted in 1:2 
cocrystal that crystallizes in P-1 space group with two independent DMG molecules. 
Unusually, no two HCT molecules interact with each other directly.  
 
Figure 5.11 Hydrogen bonding between HCT and DMG in the cocrystal. 
The carboxylate moiety of the DMG molecules connects two neighboring HCT 
molecules through N-H···COO
- 
(one N-H of the 1
o
 amine, 2.917 (3) Å and the other of 
the 2
o
 sulfonamide group, 2.860 (2) Å) as illustrated in Figure 5.11. Two such tapes as 
illustrated Figure 5.12 are connected to each other via bifurcated H-bonds formed by the 
carboxylate moiety in the first layer with the 1
o
 amine, 2.894 (3) Å and the other of the 2
o
 
sulfonamide group 2.827 (2) Å present in the second layer  between them. Similarly, the 
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carboxylate of the DMG molecule in the second layer forms bifurcated H-bonds with 
HCT present in the first layer. However, the DMG molecules (blue) which connects the 
HCT molecules in one tape is connected to another DMG molecule present in the 
adjacent tape via a dimer formed by second independent (magenta) DMG molecules by 
N-H···O
-
 ( 2.761 (2) Å) as shown in Figure 5.12. 
 
Figure 5.12 Overall H-bonding in HCTDMG. HCT molecules are colored in green, while two 
independent DMG molecules are colored in magenta and blue. 
 
5.5 Discussion 
Cocrystallization attempts of HCT resulted in the isolation of five cocrystals with CCFs 
that contain amides and carboxylate functionalities. This offer a means to explore and 
study certain functionalities like sulfonamides and carboxylates which are under explored 
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from supramolecular perspective. The only one cocrystal which was isolated as a hydrate 
was HCTINM•H2O and the stability of the cocrystal upon the removal of water from the 
crystal has been thoroughly studied in one our recent publication on hydrate cocrystals. 
The amide dimer of INM is intact in HCTINM•H2O cocrystal whereas that has been 
overcome by N-H···O supramolecular heterosynthon in HCTNAM. In HCTNAC the 
carboxylate only interacts with the N-H of the 1
o
 sulfonamide moiety whereas in 
HCTBTN and HCTDMG the carboxylate interacts with all the functional moieties 
present in HCT molecule namely, 1
o
 and 2
o
 sulfonamide moieties and 2
o 
amine. 
Carboxylic acids were not successful CCFs for cocrystallization with HCT as they were 
with many other sulfa drugs reported by Caira et al.
18
 This is understandable because 
most of the sulfa drug cocrystals contain Narom moiety in their structures that have been 
reported in the CSD. As carboxylic functionalities form a robust supramolecular 
heterosynthon with Narom moiety and this has been exemplified exemplified by one of 
our hierarchy study of supramolecular heterosynthons. According to which the carboxylic 
acid groups are more suitable for Narom moieties for cocrystallization as the chances of 
interactions between these functionalities is 97 % (in the absence of other competing 
functionalities which has been already established by Shattock et al.
26
 Some examples of 
sulfa drugs such as celecoxib, sulfathiazole and sulfadimidine are presented in Figure 
5.13 which contains sulfonamide groups fused to six or five membered ring systems with 
Narom.  While for HCT, the formation of a cocrystal depends on the reliability of 
sulfonamide (1
o
 and 2
o
), 2
o
 amine and chloride moieties to form cocrystal and makes it 
quite different from the rest.   But, we cannot rule out the possibility of carboxylic acid as 
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CCFs as the right stoichiometry, solvent and suitable method may not have been explored 
for HCT yet. 
                               
                       (a)                                                           (b)                        (c) 
Figure 5.13 Some examples of sulfa drugs containing Narom moieties in them. Celecoxib (a); 
sulfadimidine (b); sulfathiazole (c). 
 
The effect of cocrystallization on the solubility of HCT was also investigated. 
Thermodynamic solubility of the cocrystals was determined by dissolving excess amount 
of cocrystal in water for 24 h (Table 5.4). When compared to the solubility of HCT four 
cocrystals, namely HCTNAM, HCTINM•H2O, HCTBTN and HCTDMG showed an 
increase in the solubility of HCT. The highest solubility was exhibited by HCTDMG 
(1.87 mg/mL, 7-fold increase) followed by HCTBTN (1.68 mg/mL). HCTNAM and 
HCTINM•H2O exhibited almost an increase of 5-fold solubility.  
Table 5.4 Solubility and MP of HCT and its cocrystals. 
Compound 
Melting Point  
(
o
C) 
Solubility  in water 
mg/mL (24 h) 
HCT 275 0.25 
HCTBTN 220 1.68 
HCTDMG 206 1.87 
HCTINM•H2O 127 1.26 
HCTNAC 268 0.1 
HCTNAM 178 1.33 
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Surprisingly, HCTNAC displayed a lower solubility than HCT and also the highest MP 
but, the vice versa is not true. Therefore it is difficult to say that in case of HCT cocrystal 
the MP is the key factor to predict the solubility. Parameters such as crystal packing and 
MP are often times used as parameter to predict the aqueous solubility and 
viscosity.
26,27,28  
The literature contains examples of number of studies to establish a 
relationship between solubility and the MP of a compound including cocrystals.
 29,30,31
 
From various studies it is found that it is difficult to draw a correlation between such 
parameters for organic compounds as there are various other factors that control 
solubility.
32
 The complex nature of cocrystals further complicates the prediction as the 
prominent interactions in cocrystals are the intermolecular hydrogen bonds which also do 
affect the MP which in turn impacts the solubility. Similarly attempts were made to 
correlate the solubility of the cocrystal with the solubility of the cocrystal former.
33
 It was 
found that there is direct correlation between the solubility of the cocrystal components 
and the cocrystal solubility. However, limited or no such kind of correlation was 
observed in HCT cocrystals. To determine the chemical identity of the cocrystal, the 
powder obtained after 24 h was analyzed. The PXRD of the powders retrieved for 
HCTDMG and HCTBTN after 24 h reveal the dissociation of the cocrystal in to HCT 
whereas, the cocrystals HCTNAM, HCTINM•H2O and HCTNAC maintains the 
cocrystal integrity. Thus, the solubility of HCT obtained after 24 h for HCTBTN and 
HCTDMG does not reflect the solubility of the cocrystal. Future work would focus up on 
the permeability testing of HCT cocrystals. 
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5.6 Conclusion 
HCT which is quite different from other sulfa drugs in terms of acceptors and donors has 
been explored for cocrystallization. The work presented herein demonstrates how the 
basic concepts of crystal engineering could be utilized in the form of cocrystallization to 
modulate the solubility of low solubility APIs. Four new crystalline forms of HCT, a 
class IV drug have been isolated as cocrystals. The highest solubility was exhibited by 
HCTDMG whereas the lowest by HCTNAC. All the cocrystals of HCT with zwitterions 
exhibit synthon VIII where the carboxylate interacts with sulfonamide functionality. The 
results delineate that zwitterions, especially the amino acids, stand out as more 
appropriate CCFs for sulfonamide drugs like HCT (not containing Narom moiety). Amino 
acids being safe and less expensive with high water solubility make them suitable CCFs.  
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CHAPTER 6 
Ionic Cocrystals of Li salts with Homochiral and Achiral Amino Acid Zwitterions 
 
6.1 Introduction 
 
Cocrystals, “long known compounds”1 have immensely attracted the scientific 
community and are under continuous study for many applications involving, but not 
limited to, pharmaceuticals
2
, nutraceuticals
3
, hydrogels
4
, purification/chiral separations
5
, 
organic conductors
6
, dyes
7
 , luminescence
8
, sorbents
9
, organocatalysis
10
, explosives
11
 and 
non-linear optical materials
12
, photographic materials
13
. Moreover, cocrystals also 
provide a means to discover new supramolecular synthons which is the ultimate key to 
molecular assembly. Many supramolecular synthons have been discovered and new 
hierarchies are also being developed which can serve as a design tool for cocrystal 
synthesis. Until now most of the reported cocrystals consists of two organic components 
but, more recently the focus has been moved to organic-inorganic hybrid cocrystals. 
Braga et al
14
 and Zaworotko et al
15
 have reported cocrystals which consist of an organic 
molecule and an inorganic salt (especially alkali and alkaline metal salts). The coalition 
between organic and inorganic molecules results in a hybrid class of cocrystals which 
were not explored systematically until now since they were reported many decades 
before.   
6.2 Ionic cocrystals 
Nevertheless, cocrystals are considered to be one of the important outcomes of crystal 
engineering within which many research groups have focused their interest.
16,17
 A 
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cocrystal can be defined as a stoichiometric multiple component crystal formed between 
two compounds that, when pure, are solid under ambient conditions: at least one 
component is molecular and forms a supramolecular synthon with the remaining 
components via non-covalent interactions.  Primarily, non-covalent interactions include 
hydrogen bonding, coordination bonds, hydrophobic forces, π-π interactions, electrostatic 
effects and van der Waals forces. The bond strength ranges from several hundred kJ/mol 
(coordination bonds) to only a few kJ/mol (van der Waals forces).
18
 Therefore, any two 
components which adhere to the entire criterion mentioned above in the cocrystal 
definition should fall under cocrystal category. Thus, in an ionic cocrystal one of the 
component is molecular (cocrystal former 1) and the other component is an inorganic salt 
(cocrystal former 2) which interact with each other via non-covalent interactions 
including coordinate bonds. Consequently, ionic cocrystals are justified class of 
cocrystals and should be recognized as one without any discrepancy.  Though a 
serendipitous invention, ionic cocrystal gives a new perspective to look at cocrystals. 
Notwithstanding that ionic cocrystals have been isolated in the late 1940s
19
, this field 
remains relatively underexplored. Therefore, systematic study for the hybridization of 
organic-inorganic components in the context of ionic cocrystal is worth studying. 
6.3 Crystal engineering of Lithium salts 
6.3.1  Design perspective: In most of the Li complexes, lithium ions are observed to 
interact with an oxygen atom to a greater extent than to any other atoms. Complexes 
wherein lithium interacts with nitrogen or sulfur atoms are comparatively less in number. 
The order of the stability of Li complexes with ligand donor atoms oxygen, nitrogen and 
sulfur is O > N > S.
20
  Because of its small size, Li exhibits a large variety of 
126 
 
coordination numbers and geometry. The coordination numbers vary from 2 to 8 in its 
complexes and the most predominant coordination numbers are 4, 5 and 6.
25
 From an 
electrostatic point of view, the tetrahedral (Td) configuration is the most stable.
15 
Similarly, naturally occurring zeolites such as analcime, chabazite, clinoptilolite, 
heulandite, natrolite, phillipsite etc are sustained via tetrahedral nodes resulting in 3-D 
microporous networks. Inspired by nature many synthetic zeolites have been synthesized 
with a wide range of topologies by utilizing angular oxide linkers with metals in the 
stoichiometry of 2:1 ratio.
21
  
6.3.2 Drug perspective: From early 19
th
 century Li in the form of Li+ ion had been 
used as a drug for treating gout owing to its ability to dissolve uric acid crystals isolated 
from the kidneys. From the 1870s onwards it was in use for mania treatment and also 
used a antipsychotic drug with no/minimal suicidal tendencies.
22,23
 By the early 1920’s Li 
(Lithium citrate) was in use as an ingredient in soda beverages as a mood stabilizer 
marketed under names such as "Bib-Label Lithiated Lemon-Lime Soda and 7 Up. It is 
believed that once ingested Li interacts with a number of neurotransmitters and receptors 
through central nervous system which in turn decreases the release of norepinephrine and 
increases the synthesis of serotonin. But the use of Li was soon ceased due severe side 
effects. The narrow therapeutic index of Li salts limits its use as a therapeutic drug.
24
 For 
bipolar disorder the therapeutic concentration is 0.6-1.2 mEq/L and the Li toxicity could 
take place once the concentration is > 1.5 mEq/L. The Tmax for most of the Li salts the 
blood serum is about 2 h whereas for the brain is around 24 h. To make the things worse 
Li experiences difficulty in passing the blood brain barrier (BBB) and this leads to the 
accumulation of Li in various vital organs of the body. Thus, patients have to be 
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continuously monitored for Li overdose and toxicity which restricts the treatment to carry 
out for patients in smaller and continuous doses. Cocrystallization of Li salts with 
acceptable cocrystal formers such as amino acids could serve as an alternative to the issue 
mentioned above for the following reasons: (a) amino acids are transported to the brain 
via many active transporters and are therefore good choice for cocrystallization with Li 
salts; (b) cocrystals can manipulate the physico-chemical properties and could alter the 
bioavailability of Li salts via cocrystallization; (c) since cocrystals are novel and hence 
patentable; (d) amino acids have carboxylate moiety that can strongly interact with Li 
cation via coordination bond.  
In this attempt, we undertook the study of synthesizing ionic cocrystals of lithium 
salts and amino acid zwitterions. In one of our recent publications
14
, we have highlighted 
the use of homochiral and achiral amino acid zwitterions to develop a strategy for 
lithium-based ionic cocrystals with amino acid zwitterions. This strategy was 
materialized in producing 1:2 cocrystals of Li salts namely, lithium chloride (LIC), 
lithium bromide (LIB) and lithium nitrate (LIN) with amino acid zwitterions cocrystals 
with different topologies including zeolites, square grids and diamondoids. Thus, it is 
clear that stoichiometry is the key factor for determining topology in Li-amino acid 
zwitterion based cocrystals. Selection of amino acid zwitterions for cocrystal design has 
also been exemplified in some of our earlier results.
25
 The CSD contains eight ionic 
cocrystals of LIC, LIB and LIN with amino acids (LIB cocrystals = ALGLYL
26
, 
GLYGLB, GLYLIB; LIC cocrystals = HEFWUK
27
, HEFXEV, YOXBET
28
; LIN 
cocrystals = ALUNEA
29
, ROZTUW
30
). The ionic cocrystals of LIC and LIB including 
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some of the LIN with amino acids (1:1 and 1:2 cocrystals) have been reported 
elsewhere.
14,31 
6.4 Experimental Section 
 
The CCFs (with their three letter code) listed in Figure 6.1 are used for cocrystallization 
experiments for Li salts. All reagents were obtained from commercial suppliers and used 
without further purification.   
NH
2
O
OHNH2
O
OHNH2
O
OH
N
H
N
O
OH
NH
2
N
COOH
N
O
OH
NH
2
O
OHOH
Dimethylglycine (DMG)
L-Serine (SER) Histidine (HIS) Nicotinic acid (NAC)Isonicotinic acid (NAC)
N
COOH
L-Leucine (LEU)Beta Alanine (BAL) Amino butyric acid (ABA)
 
Figure 6.1 List of cocrystal formers with three letter code. 
 
6.4.1 Preparation of single crystals: Single crystals for the cocrystals are obtained by 
dissolving the starting materials in appropriate ratio in distilled water followed by 
evaporation. Specific details are as follows: 
LICLEU: Lithium chloride, anhydrous, 253.8 mg (6.0 mmol) and leucine, 40 mg (0.3 
mmol) were dissolved in 5 mL of deionized water and left on the hot plate evaporated on 
a hot plate until crystals emerged from the hot solution.  
LINABA: Lithium nitrate, 413.4 mg (6.0 mmol) and 4-aminobutyric acid, 618.6 mg (6.0 
mmol) were dissolved in 4.0 mL of hot deionized water and evaporated on a hot plate 
until crystals emerged from the hot solution. Colorless rod crystals were collected from 
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the hot solution.  
LINBAL: Lithium nitrate, 413.4 mg (6.0 mmol) and β-alanine, 534.5 mg (6.0 mmol) 
were dissolved in 2.0 mL of hot deionized water. The solution was maintained on a hot 
plate until crystals emerged from the hot solution. Colorless crystals were collected from 
the hot solution.  
LINHIS: Lithium nitrate, 413.4 mg (6.0 mmol) and L-histidine, 50 mg (0.32 mmol) were 
dissolved in 5.0 mL of hot deionised water. It was maintained on a hot plate until crystals 
emerged from the hot solution. Colorless plates were collected from the hot solution.  
LININA: Lithium nitrate, 413.4 mg (6.0 mmol) and isonicotinic acid, 40 mg (0.325 
mmol) were dissolved in 3 mL of deionised water. It was maintained on the hot plate 
until crystals emerged from the hot solution. Colorless crystals were collected from the 
hot solution and used for further analysis.  
LINNAC: Lithium nitrate, 413.4 mg (6.0 mmol) and nicotinic acid, 80 mg (0.65 mmol) 
were dissolved in 3 mL of deionised water. It was maintained on the hot plate until 
crystals emerged from the hot solution. Colorless plates were collected from the hot 
solution and used for further analysis.  
LINDMG2: Lithium nitrate, 413.4 mg (6.0 mmol) and N, N-dimethylglycine 1236 mg 
(12.0 mmol) were dissolved in 3.0 mL of hot deionised water. It was maintained on the 
hot plate until crystals emerged from the hot solution. Colorless plates were collected 
from the hot solution.  
LINSER2: Lithium nitrate (99%, anhydrous, used as received from Acros Organics, 414 
mg, 6.0 mmol) and L-serine (used as received from Acros Organics, 635.4 mg, 6.0 mmol) 
were dissolved in 3.0 mL of hot deionised water. It was maintained on the hot plate until 
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crystals emerged from the hot solution. Colorless rods were collected from the hot 
solution. 
6.4.2 Differential scanning calorimetry (DSC): Thermal analysis was performed on a 
TA Instruments DSC 2920 Differential Scanning Calorimeter. Aluminum pans were used 
for all samples and the instrument was calibrated using an indium standard. For 
reference, an empty pan sealed in the same way as the sample was used.  Using inert 
nitrogen conditions, the samples were heated in the DSC cell from 30°C to the melting 
point of the cocrystal at a rate of 10°C/min 
6.4.3 Thermogravimetric analysis (TGA): A Perkin Elmer STA 6000 Simultaneous 
Thermal Analyzer was used to conduct thermogravimetric analysis. Open alumina 
crucibles were used to heat the samples from 30°C to the required temperature at 10 
°C/min scanning rate under nitrogen stream. 
6.4.4 Infrared spectroscopy (FT-IR): Characterization of the cocrystals by infrared 
spectroscopy was accomplished with a Nicolet Avatar 320 FT-IR instrument. Sample 
amounts of 1-2 mg were used and spectra were measured over the range of 4000 – 
400cm-1 and analyzed using EZ Omnic software. 
6.4.5 Powder X-ray diffraction (PXRD): A Bruker AXS D8 X-ray powder 
diffractometer was used for all PXRD measurements with experimental parameters as 
follows: Cu Kα radiation (λ = 1.54056 Ǻ); 40 kV and 30 mA; Detector type: Scintillation 
type; Scanning interval: 3-40° 2θ; time per step: 0.2 sec. The experimental and calculated 
PXRD patterns from single crystal structures were compared to confirm the composition 
of bulk materials. 
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6.4.6 Single-Crystal X-ray Data Collection and Structure Determination: Crystals 
suitable for X-ray crystallography were selected using an optical microscope. Data for the 
cocrystals were collected on Bruker-AXS SMART APEXII CCD diffractometer with 
monochromatized Cu Kα radiation (λ = 1.54178 Å) connected to a KRYO-FLEX low 
temperature device. Indexing was performed using SMART V5.6 or using APEX 2008 
V1-0. Frames were integrated with Saint Plus 7.51 software package. Absorption 
correction was performed by multi-scan method implemented in SADABS. The 
structures were solved using SHELXS-97 and refined using SHELXL-97 contained in 
SHELXTL V6.10 and WinGX V1.70.01 programs packages. All non-hydrogen atoms 
were refined anisotropically. Hydrogen atoms were placed in geometrically calculated 
positions or found in the Fourier difference map and included in the refinement process 
using riding model or without constraints. The crystallographic data for the cocrystals 
reported herein are presented in Table 6.3. 
6.5 Crystal Structure Descriptions  
6.5.1 LICLEU: The X-ray structure reveals a 1:1 LIC and LEU cocrystal hydrate. Each 
lithium cation is coordinated by three bridging carboxylates (Li-O: 1.947 Å, 1.966 Å and 
1.981 Å). One water molecule coordinates to Li atom to complete its tetrahedral 
coordination (Li-O: 1.921 Å). The chloride anions reside in the crystal unit and 
participate in the H-bonding with the nitrogen atom in the RNH3
+
 cation of the amino 
acid (Cl···N-H: 3.169 (2) Å and 3.180 (2) Å). It also H-bonds to two water molecules of 
the adjacent tape (Cl···O-H: 3.183 (3) Å and 3.208 (2) Å). Figure 6.2 illustrates the 
overall network in LICLEU. 
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Figure 6.2 1-D tape in LICLEU monohydrate. 
 
6.5.2 LINABA: The 1:1 cocrystal of LIN and ABA cocrystallize in P21/n space group. 
Each Li atom is coordinated to two carboxylate anions of ABA with bond distances Li-O: 
1.897 and 1.946 Å.  
 
Figure 6.3 Illustration of square grids in LINABA. 
The nitrate anions acts as bridging ligands and bind to Li atom completing its tetrahedral 
geometry. The coordinate bond distances observed between the Li atom and the nitrate 
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anions are 1.975 and 2.047 Å. The overall structure in LINABA results in a square grid 
network as shown in the Figure 6.3. 
6.5.3 LINBAL: The cocrystallization of LiNO3 and beta-alanine results in the 
formation of 2:3 cocrystal. The LINBAL cocrystal also results in the formation of 1-D 
tape as in LICPRO, LICBAL-I.  
 
Figure 6.4 Formation of linear 1-D tape in LINBAL. 
The only difference being the bridging of water molecule to the metal to complete the 
tetrahedral coordination environment whereas, in LINBAL the fourth coordination of Li 
metal is satisfied by the nitrate anion. Thus, the overall coordination of BAL molecules 
and the nitrates anions to the Li atom results in the formation of a linear tape as shown in 
Figure 6.4. 
6.5.4 LINHIS: Cocrystallization between LIN and HIS results in the formation of a 1:1 
cocrystal. Each of the Li atom is coordinated to three neighboring carboxylates of HIS 
molecules.  The fourth coordination of Li is fulfilled by water molecule. Li-O distances 
(Li to carboxylate oxygen) observed in LINHIS are 1.875 Å, 1.955 Å, 1.962 Å. The 
nitrate anion resides in the crystal packing without coordinating to any atom; nevertheless 
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it is involved in H-bonding with the ammonium group (RNH3
+
) and NH moiety of the 
imidazole ring of HIS molecule. The Narom of the imidazole ring also H-bonds to the 
ammonium group (RNH3
+
). The overall coordination between LIN and HIS results in the 
formation of linear 1-D tape as presented in Figure 6.5. 
 
 
Figure 6.5 Illustration of 1-periodic network in LINHIS (hydrogen atoms have been removed for 
clarity). 
 
6.5.5 LININA: The single crystal X-ray structural analysis reveals that LININA is a 
1:1 cocrystal of LIN and INA. The tetrahedral coordination environment of the lithium 
cations were achieved by three bridging carboxylates and the nitrate anions.  If the four-
membered Li2(µ2-oxo)2 rings are considered as nodes, then the overall network could be 
described as square grids.  These nodes are bridged by carboxylates, with each 
carboxylate having one µ2-O donor and one monodentate O-donor. The Li-O coordinate 
bond distances in LININA are 1.888, 1.931, 1.963 and 1.974 Å. The sheets (grids) stack 
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along the a axis in AAA fashion and interact via hydrogen bonding.  Distance between Li 
atoms in adjacent sheets (measured along a axis) = 9.931 Å.        
 
Figure 6.6 Representation of square grids in LININA. 
 
6.3.6 LINNAC: Cocrystallization of LIN and NAC results in the formation of 1:1 
cocrystals wherein the Li atoms and the carboxylate moieties form a 4-membered ring 
with Li-O bond distance of 1.875 and 1.966 Å (Figure 6.7). LINNAC is isoreticular to 
LININA.  There is no H-bonding between sheets, resulting in a greater intersheet 
distance than LININA . 
 
Figure 6.7 Illustration of 4-memebered ring in LINNAC. 
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Distance between Li atoms in adjacent sheets (measured along a axis) = 10.326 Å. 
(slightly > than LININA).  There is intra sheet H-bonding instead. Two of the oxygen 
atoms in the nitrate ion forms a bifurcated hydrogen bond with the N-H moiety of NAC 
molecule (O···N-H: 2.815 and 2.993 Å). Similar to that of LININA, LINNAC also 
results on formation of square grids (Figure 6.8). 
 
Figure 6.8 Overall network in LINNAC. 
 
6.5.7 LINDMG2: Cocrystallization of LIN with DMG resulst in the formation of a 1:2 
cocrystal. Each of the Li atoms is coordinated to one of the oxygen atoms of the 
carboxylate moieties of four DMG molecules with Li-O bond lengths of 1.934, 1.948, 
1.952 and 1.951Å. The R2NH
+
 moiety of DMG involves in H-bonding with one of the 
oxygen atoms of carboxylate moiety of DMG as represented in Figure 6.9. The nitrate 
anion does not participate in any kind of bonding in LINDMG2. The overall bonding in 
LINDMG2 resulst in the formation of a diamondoid network. 
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Figure 6.9 Representation of overall packing in LINDMG2. 
6.3.8 LINSER2: The single crystal X-ray structural analysis reveals that LINSER2 is a 
1:2 cocrystal of lithium nitrate and L-serine. Each lithium cation is bridged by four 
carboxylates to form an undulating square grid. Each ammonium cation (R3NH
+
) forms 
hydrogen bond to the O-H functionalities of two adjacent L-serine molecules and a 
nitrate anion. Figure 6.10 represents the asymmetric unit and Figure 6.11 the overall 
network in LINSER2. 
 
Figure 6.10 Asymmetric unit of LINSER2. 
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Figure 6.11 Illustration of square grids in LINSER2. 
6.4 Discussion 
All the cocrystals of Li exhibit four-fold coordination (which is one of the most common 
coordination numbers. From our study it is observed that there is considerable flexibility 
in the overall geometry of the ionic cocrystals of Li salts with zwitterions (including 
amino acids and molecules like INA and NAC). Table 6.1 lists all the ionic cocrystals of 
Li salts with their stoichiometry and geometry. So far 26 ionic cocrystals (1:1, 1:2 and 
2:3) of LIB, LIC and LIN have been isolated six of which are hydrated cocrystals.   
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Table 6.1 List of ionic cocrystals of Li salts with their stoichiometry and geometry.  
Ionic cocrystal Stoichiometry Geometry Ionic cocrystal Stoichiometry Geometry 
LIBPRO* 1:1 1D Tape LINNAC 1:1 SQG 
LICABA 1:1 1D Tape LINPRO 1:1 DIA 
LICBAL-I* 1:1 1D Tape LINSAR 1:1 1D Tape 
LICBAL-II 1:1 1D Tape LIBDMG2 1:2 DIA 
LICDMG** 1:1 Discrete LIBPRO2 1:2 DIA 
LICLEU* 1:1 1D Tape LICDMG2 1:2 DIA 
LICPRO* 1:1 1D Tape LICPRO2 1:2 DIA 
LICSAR* 1:1 1D Tape LICSAR2 1:2 SQG 
LINABA 1:1 1D Tape LINBTN2 1:2 SQG 
LINBAL 2:3 1D Tape LINPRO2-I 1:2 ABW 
LINDMG 1:1 1D Tape LINPRO2-II 1:2 DIA 
LINHIS* 1:1 1D Tape LINDMG2 1:2 DIA 
LININA 1:1 SQG LINSER2 1:2 SQG 
* = monohydrate, ** = dihydrate 
 
Hydration is more frequently observed in 1:1 cocrystals of LIB and LIC. Only one of 
LINs cocrystal, LINHIS, formed a hydrate the remaining are anhydrates. In LIN 
cocrystals the Li atom is coordinated to three carboxylates and the fourth coordination is 
satisfied by the nitrate ion which acts as the bridging ligand. On the contrary, in most of 
the LIB and LIC cocrystals the fourth coordination is satisfied by a water molecule 
(except LICABA and LICBAL-II). In LICABA and LICBAL-II the fourth 
coordination is fulfilled by the Cl anion allowing no room for the water molecule to 
coordinate to the metal ion. The Li ion in LICDMG is coordinated by only two 
carboxylates which allows two water molecules to complete the tetrahedral coordination 
of Li atom by forming a discrete unit of eight membered ring. From this it can be 
estimated that LIN cocrystals are more resistant to hydration when compared to LIC and 
LIB cocrystals.  Only one of LINs cocrystal, LINHIS is a monohydrate while the 
remaining are anhydrates. The erratic nature of water molecule leads to the formation of 
hydrates. More often in cocrystal design whenever there is an imbalance in the number of 
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acceptors and donors, water molecules play role in satisfying the shortage thereby 
resulting in cocrystal hydrates. The formation of hydrates has intrigued many researchers 
and many have tried to address the frequency of formation
32
 including classification 
based on their structure and energetics.
33
 One such classification was done by Morris and 
Rodriguez-Hornedo
34
 where the hydrates were divided into three classes: a) channel 
hydrates in which water molecules interact with each other and form tunnels within the 
crystal lattice; b) isolated site hydrates in which water molecules are not directly 
hydrogen bonded to each other; c) metal ion associated hydrates in which water 
molecules form strong interactions with transition metals or alkali metals. Consequently, 
the 1:1 cocrystal hydrates of Li salts fall into the third category where the water 
molecules are coordinated to the metal. The only one cocrystal for which the anhydrate 
form was producible is LICBAL-II. The 1:1 LIN cocrystals (except LINHIS) as well as 
the 1:2 cocrystals escapes from forming hydrates in these cocrystals the lithium ion 
coordinates to the oxygen atom of the carboxylate moieties or to the oxygen of the 
bridging NO3
-
 ion. In LINHIS the Li cation is coordinated to oxygen atoms of three 
carboxylate moieties and the fourth coordination is fulfilled by water instead of the 
nitrate anion which is quite unusual from the rest of the LIN 1:1 cocrystals wherein the 
nitrate anion completes its coordination.  
Owing to its variability in coordination number, Li complexes display a rich 
divergence in their geometry from 0-periodic to 3-periodic.  Out of sixteen 1:1 cocrystals, 
twelve exhibit 1-D periodic tapes. In these twelve cocrystals (except LICBAL-II), the 1-
D tapes are formed by fused 6-membered rings whereas in LICBAL-II the tapes are 
generated by the fusion of 8 and 4-membered rings. However, the overall geometry 
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produced by 1:1 cocrystals are 1-D tapes. Only one cocrystal, LICDMG, forms a discrete 
unit which is further involved in H-bonding in a 3-D network. Two cocrystals LININA 
and LINNAC forms square grids and LINPRO exhibit diamondoid geometries. More 
structural diversity is observed in 1:2 cocrystals which include topologies such as ABW, 
diamondoids and square grids.  
6.5 Conclusion 
 
Ionic cocrystals represent a relatively underexplored class of cocrystals which can play 
key role material chemistry.  Ionic cocrystals of alkali metals especially metals like 
lithium are quite intriguing as it exhibits a wide range of structural diversity due to its 
small size. The oxophilic nature of lithium makes amino acids suitable cocrystal formers 
due to the presence of carboxylate moiety. It is clear from this contribution that the 
stoichiometry between the Li salts to the amino acid governs the periodicity of the 
resulting cocrystals. All of the LIB and LIC 1:1 cocrystals generate 1-periodic structures 
(1-D tapes) except LICDMG which forms a discrete unit (0-periodicity) and most of 
them undergo hydration. Whereas equimolar quantities of LIN and amino acid result in 
the formation of 1- periodic, 2- periodic (square grids) and 3-periodic structures 
(diamondoid net). Thus, ionic cocrystals are important not only in terms of crystal 
engineering perspective but also for pharmaceuticals especially zwitterionic drugs. 
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Table 6.2 Crystallographic data and structure refinement parameters for the cocrystals 
 
 LICLEU LINABA LINBAL LINHIS 
Formula C6 H13ClLiNO3 C4H9LiN2O5 C9H21Li2N5O12 C6H9LiN4O6 
MW 191.43 172.07 405.19 240.11 
Crystal system P21 P21/m Pca21 P21 
Space group Monoclinic Monoclinic Orthorhombic Monoclinic 
a (Å) 13.215 (4) 4.87360 (10) 13.290 (2) 7.5068 (9) 
b (Å) 4.9721 (15) 15.1136 (4) 5.0444 (9) 5.0385 (6) 
c (Å) 15.668 (4) 10.2399 (3) 26.107 (5) 13.6693 (16) 
 (deg) 90 90 90 90 
 (deg) 95.272 (16) 96.769 (2) 90 95.722 (5) 
 (deg) 90 90 90 90 
V /Å3 1025.1 (5) 748.99(3) 1750.2 (5) 514.44 (11) 
Dc/mg m
-3 1.228 1.526 1.538 1.550 
Z 4 4 4 2 
2 range 2.83 to 65.36 5.24 to 68.12 3.39 to 66.70 3.25 to 66.11 
Nref./Npara. 2435/223 1333/122 278/256 1674 /161 
T /K 228 (2) 293 (2) 293 (2) 293 (2) 
R1 [I>2sigma(I)] 0.0782 0.0429 0.0677 0.0658 
wR2 0.1860 0.1131 0.1596 0.1687 
GOF 1.045 1.054 1.043 1.049 
Abs coef. 3.074 1.195 1.222 1.192 
 LININA LINNAC LINSER2 LINDMG2 
Formula C6H5LiN2O5 C4H3Li0.67N4O2 C6H14LiN3O9 C8H18LiN3O7 
MW 192.06 143.73 279.14 275.19 
Crystal system P21/c P21/c P212121 Cc 
Space group Monoclinic Monoclinic Orthorhombic Monoclinic 
a (Å) 9.9315 (6) 10.320 (3) 4.8395 (4) 12.380 (4) 
b (Å) 10.0382 (6) 9.894 (3) 8.7210 (6) 15.055 (3) 
c (Å) 7.5846 (5) 7.387 (2) 26.4305 (18) 9.442 (4) 
 (deg) 90 90 90 90 
 (deg) 91.201 (4) 90.803 (15) 90 129.875 (14) 
 (deg) 90 90 90 90 
V /Å3 755.98 (8) 754.2(4) 1115.51 (14) 1350.5 (7) 
Dc/g cm
-3 1.687 1.899 1.662 1.353 
Z 4 4 4 4 
2 range 4.45 to 63.78 4.28 to 66.71 3.34 to 67.88 5.51 to 65.07 
Nref./Npara. 1250/127 1277/128 1950/217 2180/176 
T /K 293 (2) 293 (2) 100 (2) 100 (2) 
R1 [I>2sigma(I)] 0.0436 0.0890 0.0326 0.0860 
wR2 0.1097 0.2257 0.1071 0.2062 
GOF 0.923 0.999 0.637 1.053 
Abs coef. 1.278 1.325 1.366 1.002 
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Solid state characterization of CFAINM•2H2O 
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Solid state characterization of CFAINZ 
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Solid state characterization of CFAGAH 
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Solid state characterization of EGLDMP 
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Solid state characterization of EGLGAH 
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Solid state characterization of EGLINZ•2H2O 
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Solid state characterization of MGLGAH  
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Solid state characterization of MGLINZ 
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Solid state characterization of PCAGAH 
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Solid state characterization of PGLDMP 
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Solid state characterization of PGLGAH•2H2O 
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Solid state characterization of COUNAM 
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Solid state characterization of COUINM-I 
 
 
 
 
 
DSC IR 
 
5 10 15 20 25 30 35 40
0.0
0.2
0.4
0.6
0.8
1.0
1.2
COUINM_Expt (298 K)
COUINM_Cal (100 K)
R
e
la
ti
v
e
 i
n
te
n
s
it
y
2 
 
 
 
 
PXRD TGA 
 
 
 
 
 
179 
 
 
 
 
Solid state characterization of COUINM-II 
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Solid state characterization of COUINZ 
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Solid state characterization of COUTHP-III 
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Solid state characterization of COUTBR•2H2O 
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Solid state characterization of COUTBR 
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Solid state characterization of COUURE 
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Solid state characterization of COUBTN 
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Solid state characterization of COUINA 
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Solid state characterization of HCTNAM 
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Solid state characterization of HCTNAC 
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Solid state characterization of HCTBTN 
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Solid state characterization of HCTDMG 
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Solid state characterization of LINABA 
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Solid state characterization of LINBAL 
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Solid state characterization of LINHIS 
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Solid state characterization of LININA 
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Solid state characterization of LINNAC 
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Solid state characterization of LINSER2 
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